Debilitating Symptom Complexes Attributed to Ticks (DSCATT) Clinical Pathway

Australian Government
Department of Health

FINAL CLINICAL PATHWAY
October 2020
ACKNOWLEDGEMENTS

In the spirit of respect and reconciliation, Allen + Clarke acknowledges and pays respect to the Traditional Custodians of Australia – the Aboriginal and Torres Strait Islander people, and their continuing connection to land, waters, sea and community.

Allen + Clarke sincerely acknowledges and thanks all the stakeholders for being so generous with their time and their contributions during consultations to develop and further refine the DSCATT Clinical Pathway.
This page is intentionally blank.
Debilitating Symptom Complexes Attributed to Ticks (DSCATT) Clinical Pathway

(Note: Patients may be on multiple parts of the pathway simultaneously)

Target population: Patients of all ages presenting at primary care with new onset (e.g. fever, rash) or unresolved debilitating symptoms, +/- history of tick bites

---

Initial assessment and support

Note that patients entering the pathway may come from various entry points and other pathways.

History – include specifically: +/- history of tick bite and international and domestic travel and activity history (e.g. bushwalking)

Clinical examination – specifically check presence of tick bite, rash and enlarged lymph nodes

Exclusion – obvious acute/chronic diagnosable conditions

Clinical advice – assist patient with symptom management

Treatment – obvious diagnosable conditions

Referral and follow-up and/or other care as required

See section 2

---

DSCATT Clinical Pathway

Differential diagnosis

If history of travel to overseas Lyme disease endemic area and relevant symptoms, suspect Lyme disease

See section 3.1

If relevant symptoms but no travel overseas through a Lyme disease endemic area, then suspect other tick-borne disease

See section 3.2

Consult with appropriate expert in tick-borne diseases including specialist microbiologists with diagnostic expertise

---

Diagnostic testing

Refer for testing for Lyme disease

See section 4.1

Refer for testing for other tick-borne diseases

See sections 4.2

Diagnostic testing to determine differential diagnosis according to normal clinical practice

See section 4.3

---

Diagnosis +/- referral

Confirmed diagnosis

Seek advice from a specialist microbiologist or ID physician in regards to appropriate investigation and clinical management of Lyme disease

See section 6.1

No confirmed diagnosis

Manage any ongoing symptoms of Lyme disease with ID physician advice

See sections 7.1

Confirmed diagnosis

Seek advice from a specialist microbiologist or ID physician in regards to appropriate investigation and clinical management of tick-borne disease

See section 6.2

No confirmed diagnosis

Manage any ongoing symptoms of tick-borne disease with ID physician advice

See section 7.2

---

Ongoing management

Symptoms resolve

Evaluate new symptoms that arise

---

EXIT CLINICAL PATHWAY
SUMMARY INFORMATION

The Debilitating Symptom Complexes Attributed to Ticks (DSCATT) Clinical Pathway has been developed to support decision-making on differential diagnosis and referral pathways for patients presenting with either new onset or unresolved debilitating symptoms with or without a history of tick bites and that cannot be attributed to another condition (acute or chronic). The DSCATT Clinical Pathway is not instructive; rather a tool/pathway to help structure assessments and management of patients with a wide variety of symptoms and severity of disability.

Initial assessment

- Follow usual clinical assessment practice including a travel history and activity history (e.g. bushwalking).
- A thorough subjective and objective examination will assist in forming a differential diagnosis.
- Tick bite diagnoses are challenging as clinical features can be similar to many other diseases (infectious and non-infectious). Consult with appropriate experts in vector-borne diseases including specialist microbiologists with diagnostic experience and infectious disease (ID) physicians for treatment of diagnosed vector-borne diseases.
- Seek advice from a specialist microbiologist or ID physician regarding clinical management, especially consideration of prophylactic antibiotics, for patients presenting with a tick bite or possible erythema migrans (EM). Prescribing of antibiotic treatments must be based on best practice and appropriate use of antibiotic treatments.
- DSCATT is not a diagnosable disease or a clinical diagnosis, rather it is a term used to describe symptoms of a chronic debilitating illness, often associated with a tick bite. The most common unexplained symptoms reported by patients experiencing the symptom complex described as DSCATT include fatigue, disordered thinking, sensory disturbance, arthralgia and headache. These symptoms can have multiple different causes, depending on the particular symptoms, cluster, and timeframe of symptoms.

Lyme disease (only patients who have travelled overseas to Lyme disease endemic areas)

- In patients presenting with a history of travel to Lyme disease endemic areas (Europe, North America, Asia), exposure to tick bites and with relevant clinical symptoms, suspect Lyme disease. Do NOT test for Lyme disease if patients have NOT travelled to Lyme disease endemic areas as tests may show false positives, with a risk of missing an alternative diagnosis and providing inappropriate treatment. It is important to ensure that conditions such as tumours, multiple sclerosis and motor neurone disease are not misdiagnosed as Lyme disease.
- As there is no person-to-person transmission of classical Lyme disease, the risk to Australia and Australians is low.
- For patients presenting with a bull’s-eye rash (erythema migrans) and a relevant travel history, seek advice from a specialist microbiologist or an ID physician in regards to the appropriate investigations and treatments that are clinically relevant to the patient’s presentation and commence antibiotic therapy.
- Diagnostic testing for Lyme disease should only be initiated following advice from appropriate experts such as a consultant ID physician or a specialist microbiologist and should only be undertaken in Australia in a pathology laboratory accredited by National Association of Testing Authorities, Australia (NATA) and Royal College of Pathologists of Australasia (RCPA) to conduct such testing.
- NATA accreditation is highly regarded both nationally and internationally as a reliable indicator of technical competence. All pathology laboratories in Australia receiving funding via Medicare must be accredited by the NATA/RCPA Laboratory Accreditation Program. The Standards are set by the National Pathology Accreditation Advisory Council (NPAAC). The quality management aspects of the NPAAC requirements are based on the international standard AS ISO 15189 Standard for Medical Laboratories. NATA accredited laboratories can detect tick-borne illnesses.
- If there is no EM, a course of antibiotic treatment for Lyme disease should only be initiated based on the expert advice of either a consultant ID physician or a specialist microbiologist. This advice will be based upon results of confirmatory testing conducted in a NATA/RCPA accredited laboratory and/or other clinical findings relevant to informing a treatment decision.
• For patients with ongoing symptoms after one course of antibiotics (course duration as defined by best practice), only one additional course of antibiotics may be recommended as there is no evidence of benefit of longer courses. An additional course of antibiotics should be determined case by case. Full resolution of symptoms may take some time but does not require further antibiotics.

• Therapeutic modalities not recommended for treatment of patients with any manifestation of Lyme disease include combinations of antimicrobials, long-term antibiotic therapy, hyperbaric oxygen, fever therapy, intravenous immunoglobulin, ozone, cholestyramine, energy and radiation-based therapies, vitamins and nutritional managements, magnesium and bismuth injections, chelation and heavy metal therapies, stem cell transplants.

Tick-borne diseases known to be acquired in Australia

• In patients who have not travelled overseas to Lyme disease endemic areas AND who have or may have been recently bitten by a tick in the past or who engage in activities such as bushwalking AND present with relevant acute or chronic symptoms, suspect Australian tick-borne diseases and seek expert advice as per above.

• Diagnosis of tick-borne disease known to exist in Australia is challenging. Symptoms may overlap with other infectious diseases including those that are transmitted by non-tick vectors as well as a number of chronic diseases. Seek further expert opinion as necessary depending upon the nature of the patient’s clinical presentation. Apart from the occasional local bacterial infection at the tick bite site (eschar) the only two systemic infections that are definitely known to be transmitted by tick bites in Australia are Rickettsial infections from infection with Rickettsia spp. (Queensland Tick Typhus, Flinders Island Spotted Fever and Australian Spotted Fever) and Q fever (Coxiella burnetii).

• Queensland Tick Typhus (QTT), early recognition and treatment is important – see Therapeutic Guidelines antibiotic for treatment.

• Flinders Island Spotted Fever (FISF) and Australian Spotted Fever (ASF) – see Therapeutic Guidelines antibiotic for treatment.

• Q fever (Coxiella burnetii) – see Therapeutic Guidelines antibiotic for treatment. Q fever is a nationally notifiable disease. Q fever is acquired via various modes of transmission, a minority of which is tick-borne.

Tick removal and bite prevention

• If a tick has embedded in the patient’s skin and remains in situ, enquire whether the patient suffers from allergies to ticks before attempting to remove the tick. It is vital that anyone with a known tick allergy seek urgent medical attention as soon as they are aware of an attached tick and not attempt to remove it without medical help. For patients with known tick allergies, removing the tick must occur in a medical facility with capacity to initiate advanced life support in the event of anaphylaxis.

• Once a tick is found attached, patients should be advised not to touch, scratch or try to remove the tick, which should be left as undisturbed as possible. Several years of experience at Sydney hospital emergency departments using ether sprays to freeze attached adult ticks has proven highly successful in killing ticks in situ and substantially reducing the risk of allergy/anaphylaxis.

• The best way to prevent tick bites is to avoid tick-infested areas. If this is not possible patients should be advised to wear appropriate clothing such as long sleeve shirt, long pants tucked into socks and light coloured clothing to make it easier to see ticks before they attach to skin.

• Insecticides containing either diethyl-meta-toluamide (DEET) or picaridin should be applied to the skin prior to entering a tick infested area. Permethrin treated clothing is considered the most effective means of tick bite prevention. Higher concentrations of DEET are not necessarily more effective, but are longer lasting.

Australian and other international vector-borne diseases

• In patients who have recently returned from international travel AND who have or may have been recently bitten by a vector such as a mosquito AND present with acute onset symptoms, suspect international vector-borne disease AND seek expert advice, as above. Check whether the history of travel aligns with either epidemic or endemic areas for other vector-borne diseases. Consider overseas-acquired tick-borne diseases such as:
  - Relapsing fever borreliosis
  - Rickettsial diseases
- Anaplasmosis
- Babesiosis
- Tularaemia
- Tick-borne encephalitis.

- Patients considered for such suspected diseases are not covered by this Clinical Pathway.
- In patients who have not travelled overseas recently AND who have or may have been recently bitten by a vector such as a mosquito AND present with acute onset, suspect Australian vector-borne disease AND seek medical advice as above.

**Mosquito-borne disease**

- While some mosquito-borne diseases are locally acquired in Australia, others are imported to Australia when people acquire the disease travelling overseas and return unwell.
- Some types of mosquitoes can transmit viruses such as Ross River and Barmah Forest in most parts of Australia and, rarely, the virus that causes Murray Valley encephalitis. Some parts of northern Queensland have a type of mosquito (Aedes aegypti) that is capable of transmitting dengue fever, chikungunya and zika infections. Dengue outbreaks have known to occur from time to time in Queensland while chikungunya and zika are only seen in imported cases.
- Mosquito-borne diseases are notifiable to public health authorities. If clinically suspected, seek appropriate expert advice where necessary on both appropriate sampling and testing that should be requested to confirm diagnosis.
- Overseas travellers may be at risk of mosquito-borne diseases such as malaria, dengue, yellow fever, chikungunya, or zika. While vaccines are available for some diseases (e.g. yellow fever and Japanese encephalitis) and chemoprophylaxis medicine can help prevent malaria, all travellers should also use repellents and other general protective measures to avoid mosquito bites. The same general protection measures also apply to locally acquired mosquito-borne disease.

**Management of patients who have persistent symptoms or remain undiagnosed**

- If the symptoms are medically unexplained, general practice should treat and manage symptoms according to common best-practice and provide person-centred, stepped care. Stepped care includes:
  - developing an individualised, time contingent, care plan
  - actively managing symptoms to improve the functioning of the patient in accordance with evidence-based guidelines
  - offering a variety of support options for people with different levels and types of need, from low intensity to high intensity
  - providing clear pathways between these care options as individuals’ needs change
  - intensifying stepped care as required by referring to relevant specialists
  - providing regular follow-up and exploring symptoms if recovery stagnates
  - reviewing new symptoms for information that may lead to diagnosis, or for indications of a new disease process.
- Where symptoms are medically unexplained, good communication and empathy are important. Take each patient’s concerns seriously and acknowledge and alleviate their symptoms.
- Patients with medically unexplained symptoms (MUS) may need support to manage distressing symptoms and any disability that accompanies the symptoms. Acknowledging the difficulty of chronic symptoms and supporting the important mental health strategies is vital to person centred care in chronic disease.
- Practice harm minimisation by avoiding fragmented care from multiple different practitioners; repeated diagnostic testing; use of non-accredited laboratories for diagnostic testing and use of unconventional diagnostic techniques; unnecessary referrals and interventions; and treatments with known harm and/or no benefit.
- The management plan for patients who have persistent symptoms or remain undiagnosed would be led by the patient’s general practitioner (GP), in consultation with the patient so the patient can achieve their goals. However, management of ongoing symptoms should involve a multidisciplinary approach, incorporating the
teamwork of all medical specialties and skills relevant to the individual patient’s care. The management of patients must be a collaborative approach between GPs and specialists. Telehealth can also be used where appropriate.

- Consider referring patients who have medically unexplained symptoms to appropriate specialists based on best clinical practice and relevant evidence.

**Periodic review of the Clinical Pathway**

- This DSCATT Clinical Pathway on Lyme disease, known Australian tick-borne diseases and the management of patients for whom a diagnosis cannot be established and who have persistent symptoms is informed by the current peer-reviewed evidence base and Australian and international authority guidance.

- There is a number of research projects currently in place to further understand the aetiology and pathophysiology of the symptom complex described as DSCATT so as to improve the diagnosis, treatment and management.

- Should the evidence base change significantly this Clinical Pathway may be reviewed.
CONTENTS

FIGURES XI

GLOSSARY XII

1. INTRODUCTION 1
   1.1. Purpose of the Clinical Pathway 1
   1.2. Debilitating symptom complexes attributed to ticks (DSCATT) 2
   1.3. Consideration of tick-borne diseases in the differential diagnosis 2
   1.4. Lyme disease 2
   1.5. Known Australian tick-borne diseases 3
   1.6. Management of patients with persistent symptoms or who remain undiagnosed 3

2. INITIAL ASSESSMENT AND SUPPORT 4
   2.1. Follow usual clinical assessment practice including a travel history 4
   2.2. Consult with appropriate experts in vector-borne disease 5
   2.3. Signs and symptoms associated with DSCATT 5

3. DIFFERENTIAL DIAGNOSIS 6
   3.1. Lyme disease 6
      3.1.1. Transmission and geographical distribution of Lyme disease 6
      3.1.2. Clinical presentation of Lyme disease 8
      3.1.3. Other presentations and considerations in diagnosing Lyme disease 11
      3.1.4. Situation in Australia in considering a differential diagnosis of Lyme disease 12
      3.1.5. Consult with appropriate Australian experts in infectious diseases 12
      3.1.6. If EM rash is present and following appropriate expert advice, offer antibiotic treatment 13
   3.2. Tick-borne disease known to be acquired in Australia 13
      3.2.1. Suspect tick-borne disease if relevant symptoms but no overseas travel through a Lyme disease endemic area 13
      3.2.2. Diagnosis of tick-borne disease known to exist in Australia is challenging 14
      3.2.3. Queensland Tick Typhus (QTT) 14
      3.2.4. If QTT suspected, following advice from appropriate experts, start antibiotic therapy (see Therapeutic Guidelines: Antibiotic) 16
      3.2.5. Australian Spotted Fever (ASF) 17
      3.2.6. Flinders Island Spotted Fever (FISF) 17
      3.2.7. Q fever 18
      3.2.8. If Q fever suspected clinically (appropriate symptoms AND at high risk epidemiologically), commence empirical treatment while waiting for laboratory tests 21
   3.3. Patients presenting with persistent debilitating symptoms and no diagnosis 21
      3.3.1. If tick-borne disease is not suspected, consider alternative diagnoses 21

4. DIAGNOSTIC TESTING 22
   4.1. Lyme disease 22
      4.1.1. Refer for laboratory testing for Lyme disease using a two-tier serology test in a NATA/RCPA accredited laboratory 22
      4.1.2. Provide advice to patients about the tests for Lyme disease 24
      4.1.3. Commercially available laboratory testing methods to be avoided 25
   4.2. Tick-borne disease known to be acquired in Australia 25
      4.2.1. Refer for testing for known Australian tick-borne diseases 25
   4.3. Patient presenting with persistent debilitating symptoms and no diagnosis 26

5. DIAGNOSIS 27
   5.1. Lyme disease 27
5.1.1. Confirmed diagnosis 27
5.1.2. No confirmed diagnosis of Lyme disease and symptoms resolve 27
5.1.3. No confirmed diagnosis of Lyme disease and symptoms persist 27
5.2. Tick-borne diseases known to be acquired in Australia 28
5.3. Patient presenting with persistent debilitating symptoms - diagnosis of specific disease(s) is established 29
5.4. Patient presenting with persistent debilitating symptoms - no diagnosis is established and medically unexplained symptoms persist 29

6. **INITIAL MANAGEMENT** 30
6.1. Lyme disease 30
   6.1.1. International guidelines for the treatment of Lyme disease 30
   6.1.2. Relevance of international guidelines to the Australian setting 31
   6.1.3. Therapeutic modalities not recommended for treatment of patients with any manifestation of Lyme disease 31
6.2. Tick-borne disease known to be acquired in Australia 33
6.3. Management of patients with persistent symptoms and who remain undiagnosed 33
   6.3.1. Medically Unexplained Symptoms 34
   6.3.2. Practice Harm Minimisation 35
   6.3.3. The Stepped Care Model 39

7. **ONGOING MANAGEMENT** 42
7.1. Lyme disease 42
7.2. Tick-borne disease known to be acquired in Australia 43
7.3. Management of patients with persistent symptoms and who remain undiagnosed 44

**APPENDIX A: CASE STUDIES** 45
   Case Study 1 – Rickettsiae infection 45
   Case Study 2 45

**APPENDIX B: BIBLIOGRAPHY** 46
TABLES

Table 1: Stages of Lyme disease in patients who have travelled to Lyme disease endemic countries 10
Table 2: Other signs and symptoms of Lyme disease 11
Table 3: Initial treatment of Australian tick-borne diseases 33
Table 4: Recommendations for managing medically unexplained symptoms 37
Table 5: Overview of Stepped Care approach to managing medically unexplained symptoms 41

FIGURES

Figure 1: Distribution of Queensland Tick Typhus 15
Figure 2: Distribution of Australian Spotted Fever 17
Figure 3: Distribution of Flinders Island Spotted Fever 18
## Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASF</td>
<td>Australian Spotted Fever</td>
</tr>
<tr>
<td>CBT</td>
<td>Cognitive behavioural therapy</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CDNA</td>
<td>Communicable Diseases Network Australia</td>
</tr>
<tr>
<td>DEET</td>
<td>Diethyl-meta-toluamide</td>
</tr>
<tr>
<td>DSCATT</td>
<td>Debilitating Symptom Complexes Attributed to Ticks</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EM</td>
<td>Erythema Migrans. Bull’s Eye Rash</td>
</tr>
<tr>
<td>FISF</td>
<td>Flinders Island Spotted Fever</td>
</tr>
<tr>
<td>GI</td>
<td>Glycaemic Index</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>ID</td>
<td>Infectious Disease</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IgM</td>
<td>Immunoglobulin M</td>
</tr>
<tr>
<td>IDSA</td>
<td>Infectious Diseases Society of America</td>
</tr>
<tr>
<td>IDSA/AAN/ACR</td>
<td>Infectious Diseases Society of America (IDSA)/American Academy of Neurology (AAN)/American College of Rheumatology (ACR)</td>
</tr>
<tr>
<td>MBS</td>
<td>Medical Benefits Schedule</td>
</tr>
<tr>
<td>MUS</td>
<td>Medically Unexplained Symptoms</td>
</tr>
<tr>
<td>NATA</td>
<td>National Association of Testing Authorities, Australia</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence (UK)</td>
</tr>
<tr>
<td>NHMRC</td>
<td>National Health and Medical Research Council</td>
</tr>
<tr>
<td>NRL</td>
<td>National Serology Reference Laboratory</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerised Chain Reaction</td>
</tr>
<tr>
<td>RACGP</td>
<td>Royal Australian College of General Practitioners</td>
</tr>
<tr>
<td>RCPA</td>
<td>Royal College of Pathologists of Australasia</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>TGA</td>
<td>Therapeutic Goods Administration</td>
</tr>
<tr>
<td>QFS</td>
<td>Q Fever Fatigue Syndrome</td>
</tr>
<tr>
<td>QTT</td>
<td>Queensland Tick Typhus</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

1.1. Purpose of the Clinical Pathway

This evidence-based Clinical Pathway has been developed to support decision-making on differential diagnosis and referral pathways for patients presenting with either new onset or unresolved debilitating symptoms with or without a history of tick bites that cannot be attributed to another condition (acute or chronic). The Clinical Pathway is not instructive; rather it is a tool/pathway to help structure assessments and management of patients with a wide variety of symptoms and severity of disability. It has also been designed specifically for the Australian health care context in order for it to be generally accepted by the Australian medical and other health professions and patient groups as a part of their clinical management.

This DSCATT Clinical Pathway on Lyme disease, known Australian tick-borne diseases and the management of patients for whom a diagnosis cannot be established and who have persistent symptoms is informed by the current peer-reviewed evidence base and Australian and international authority guidance.

The information and recommendations on the diagnosis and management of Lyme disease in this Clinical Pathway include both Australian and international authority guidelines. The most recently published evidence-based international guidelines for the diagnosis and management of Lyme disease included in the Clinical Pathway are the 2018 National Institute for Health and Care Excellence (NICE) Lyme disease guideline and the 2019 Draft Infectious Diseases Society of America (IDSA)/American Academy of Neurology (AAN)/American College of Rheumatology (ACR) Lyme disease guideline, both of which are underpinned by evidence-based reviews of the literature. The advice and recommendations from the 2019 IDSA/AAN/ACR Lyme disease guidelines are clearly marked ‘Draft’. If IDSA/AAN/ACR make any changes during finalisation of the guidelines, any such changes will be made to this Clinical Pathway.

There is a number of research projects currently in place to further understand the aetiology and pathophysiology of the symptom complex described as DSCATT so as to improve the diagnosis, treatment and management. The Australian Government acknowledged the need for targeted research to further understand the chronic symptoms experienced by many Australians and which are associated with tick bites. In January 2019, the Government invested nearly $3 million over five years for research to better understand the nature, prevalence and causes of these symptoms with the longer-term aim to obtain evidence to guide development of treatments:

- Professor Peter Irwin of Murdoch University received more than $1.9 million for research to determine the causes of DSCATT, including improved diagnostic outcomes for patients bitten by ticks through the provision of accurate and evidence-based information about their illness.
- Professor Richard Kanaan of the University of Melbourne received more than $1 million to develop a new treatment for DSCATT, including a case definition, adapt the treatment approach for unexplained syndromes to the specifics of DSCATT, and then pilot a randomised controlled trial to test the effectiveness of the new therapy.¹

Should the evidence base change significantly the Clinical Pathway may be reviewed.

---

¹ Department of Health (2019, 5 January)
1.2. Debilitating symptom complexes attributed to ticks (DSCATT)

Debilitating symptom complexes attributed to ticks (DSCATT) is the term used by the Australian Government to describe the group of Australian patients suffering from the symptoms of a chronic debilitating illness, which many associate with a tick bite, to appropriately acknowledge this patient group and the multifaceted illness they are experiencing, and acknowledge their illness is poorly understood. The Australian Government acknowledges that many of these patients experiencing debilitating symptom complexes are living in turmoil because their illness cannot be easily diagnosed and treated. With the causes of DSCATT remaining unknown, the Australian Government urges patients and health professionals to keep an open mind about the cause of a patient’s symptoms.

DSCATT was also proposed as a name to move away from the stigma and controversy associated with the terms previously used to describe this patient’s group such as “Lyme disease-like Illness” and “Chronic Lyme Disease”.

DSCATT is not a diagnosable disease and a patient cannot be given a diagnosis of DSCATT.

DSCATT is not clearly defined and is not formally reported. It has no diagnostic criteria, known cause or causes, no treatment and associated symptoms may be the end point for several different disease processes. The symptom complexes to which the name DSCATT has been given incorporates a wide range of nonspecific symptoms. Symptoms and signs associated with DSCATT are detailed in Section 2, Initial Assessment and Support. Some people may have a diagnosis that has not yet been identified that explains these symptoms while others may have a cluster of medically unexplained symptoms that require management.

People with medically unexplained symptoms (MUS) may obtain a diagnosis over time as symptoms develop and guide to the origin of the illness. Others may find that symptoms resolve over time, without ever identifying a cause. All people with medically unexplained symptoms, (including those experiencing the symptoms associated with DSCATT) can be assisted to have an improved quality of life with good care in a partnership between patient and the health care team.

1.3. Consideration of tick-borne diseases in the differential diagnosis

Acknowledging the attribution to ticks in the term DSCATT, this Clinical Pathway includes the consideration of tick-borne diseases in the differential diagnosis (overseas-acquired Lyme disease, and known Australian tick-borne diseases) and considerations and referral pathways for patients for whom a diagnosis for their symptoms may not be established.

1.4. Lyme disease

Lyme disease is endemic in parts of the USA, Europe and Asia. A person visiting a Lyme disease endemic area may become infected with Borrelia burgdorferi sensu lato through a tick bite and subsequently develop Lyme disease. Overseas travellers to Lyme disease endemic areas may return to their home country before becoming symptomatic and/or being diagnosed.

Despite multiple studies which have thoroughly searched for it in Australian ticks and patients, the organisms that cause Lyme disease have not, to date, been identified in Australian ticks nor any other vector that could transmit the disease to humans. It is for this reason that the Australian

---

2 Department of Health (2018a)
3 Ibid
medical profession does not support the diagnosis of locally acquired Lyme disease in Australia. While some Australians and healthcare providers believe that a form of ‘chronic Lyme disease’ exists, globally, ‘chronic Lyme disease’ is a disputed diagnosis which lacks sufficient supporting evidence.

1.5. Known Australian tick-borne diseases

Apart from the occasional local bacterial infection at the tick bite site (eschar) the only two systemic infections that are definitely known to be transmitted by tick bites in Australia are Rickettsial infections from infection with *Rickettsia* spp. (Queensland Tick Typhus, Flinders Island Spotted Fever, Australian Spotted Fever) and Q fever (*Coxiella burnetii*).

The signs and symptoms of Rickettsial infections in Australia include eschar, fatigue, fever, headache, myalgia and rash (macular, papular, vesicular) although the severity and duration of Rickettsial diseases vary considerably. Queensland Tick Typhus (QTT) and Australian Spotted Fever (ASF) have similar core clinical manifestations with a range of other symptoms observed. Early clinical features are often non-specific, making diagnosis challenging. Additionally, symptoms may overlap with other infectious diseases including those that are transmitted by non-tick vectors as well as a number of chronic diseases.

Seek further expert advice from appropriate experts in vector-borne diseases as necessary.

1.6. Management of patients with persistent symptoms or who remain undiagnosed

The Clinical Pathway acknowledges that because of the imprecise nature of the symptom complexes some patients will remain undiagnosed. Therefore, evidence-based ways to manage ongoing symptoms through a comprehensive patient-centred care plan has been included for patients for whom there is no diagnosis and who are considered to have medically unexplained symptoms or ‘undiagnosed illness’.

Where there is no diagnosis, and the patient is experiencing symptoms that are medically unexplained, it is especially important to ensure that patient or person-centred care is provided to validate, address and manage their symptoms as well as possible. Good communication and empathy are important. Take patients concerns seriously and acknowledge and alleviate their symptoms. Provide support to manage distressing symptoms and any disability that comes with them.

The management plan for patients who have persistent symptoms or remain undiagnosed should be led by the patient’s general practitioner (GP), in consultation with the patient so the patient can achieve their goals.

However, management of ongoing symptoms should involve a multidisciplinary approach, incorporating the teamwork of all colleges of physicians relevant to the individual patient’s care. Diagnosis is challenging, and it is important for GPs to seek opinions of experts in vector-borne diseases including specialist microbiologists with diagnostic experience and infectious disease (ID) physicians. The management of patients must be a collaborative approach between GPs and specialists. Telehealth can also be used where appropriate.

Consider referring patients who have MUS to appropriate specialists based on best clinical practice and relevant evidence.
2. **INITIAL ASSESSMENT AND SUPPORT**

The initial assessment and support for a patient who presents at primary care with new onset of fever or rash or persistent debilitating symptoms (with or without a history of tick bites) should follow usual clinical practice. The Clinical Pathway is to assist GPs with the diagnosis and management of patients who are assessed to be clinically stable.

2.1. **Follow usual clinical assessment practice including a travel history**

Initial assessment and support should include the following:

- in the clinical examination of an acute case, specifically check for the presence of tick bite or other rashes
- from the history and examination, exclude obvious acute illnesses or chronic diagnosable conditions
- treat obvious diagnosable conditions
- provide clinical advice to assist patient with symptom management while investigating any differential diagnoses, and
- arrange referral and follow-up and/or other care as required.

The inclusion of a travel history as part of the clinical history is important, as despite multiple studies which have thoroughly searched for it in Australian ticks and patients, the organisms that cause Lyme disease have not, to date, been identified in Australia, but are endemic in parts of the USA, Europe and Asia. Not all persons with Lyme disease recall having had a tick bite or notice a tick bite, thus a history of travel or exposure in a known endemic area for Lyme disease should be sought from possible cases. Lack of a tick bite history was found to not reliably exclude Lyme disease in a very recent prospective study involving children in the United States (a Lyme disease endemic area); only a minority (18.5 per cent) of children diagnosed with Lyme disease had a recognised tick bite as recalled by the child or their parents within the year prior to the child’s emergency department evaluation for Lyme disease. If a person presents with symptoms that suggest the possibility of Lyme disease, explore how long the person has had the symptoms and their history of possible tick exposure, and ask about activities that might have exposed them to ticks, and travel to areas where Lyme disease is known to be highly prevalent.

In patients who have not travelled internationally and present with symptoms suspicious for an Australian tick-borne disease, knowledge of where the patient has travelled in Australia will assist with differential diagnosis. Mosquito-borne diseases may present in the acute phase very similarly and a person who is at risk of tick bites is also likely to be at risk of mosquito bites which can appear very similar if the tick is not actually stuck on the skin, particularly if the wound is inflamed and scratched. It is recommended that medical practitioners keep an open mind when patients speak of symptoms associated with tick bites as while the patient may have other underlying medical issues brought to light at the time of the tick bite, a considered investigation of the whole clinical history is indicated.

---

4 Royal College of Pathologists of Australasia (RCPA) (2019)
5 Nigrovic et al. (2019)
6 National Institute for Health and Care Excellence (NICE) (2018a)
7 Graves & Stenos (2017)
Consult with appropriate experts including specialist microbiologists or ID physicians in regard to clinical management, especially consideration of prophylactic antibiotics, for patients presenting with tick bite or possible erythema migrans (EM). Prescribing of antibiotic treatments must be based on best practice and appropriate use of antibiotic treatments.

Note that to minimise antibiotic resistance, Australian guidelines recommend that an antibiotic should only be prescribed:  
- when benefits to the patient are likely to be substantial
- with the narrowest spectrum to treat the likely pathogen, and
- at the appropriate dose and for the appropriate duration.

2.2. **Consult with appropriate experts in vector-borne disease**

Tick bite diagnoses are challenging as clinical features can be similar to many other diseases (infectious and non-infectious). Consult with appropriate experts in vector-borne diseases including specialist microbiologists with diagnostic experience and ID physicians for treatment of diagnosed vector-borne diseases.

2.3. **Signs and symptoms associated with DSCATT**

There are no peer-reviewed published epidemiological or clinical studies about patients experiencing DSCATT. The only relevant information available is self-reported and anecdotal. Patients have told of the symptoms they have experienced and attribute to DSCATT to the Senate Community Affairs References Committee,\(^9\) \(^10\) DSCATT Patient Forum\(^11\) and Think Tank.\(^12\) The most common symptoms described by patients with DSCATT to the Senate Forum were: fatigue (62.6 per cent); disordered thinking (51.9 per cent); sensory disturbance (46.1 per cent); arthralgia (45.6 per cent); headache (44.5 per cent); followed by myalgia; rash; mood disturbance; visual disturbance; dizziness; pain; fever; nausea; palpitations; insomnia; seizures; diarrhoea; tremor; and personality change.\(^13\) Patients reported having experienced symptoms for a median of 10 years and had seen a median of 13 doctors for diagnosis and treatment of their illness. An analysis of the Senate submissions noted the unquestionable real and debilitating physical and social harm from illness reported in the submissions. Of relevance to the attribution of symptoms to ticks, over half of the submissions analysed did not comment on tick bite but of those that did, a majority (89.5 per cent) reported a positive history. The author's conclusion suggested that patients who identified as having DSCATT displayed a symptomology similar to 'medically unexplained physical symptoms' syndromes, and also experience social and financial harms and are at risk of nosocomial harms. They may also have sought alternative and potentially non-evidence-based diagnoses and treatments.\(^14\)

Similarly, multiple symptoms and signs being attributed to DSCATT were identified by stakeholders who attended the Think Tank in May 2019, with neurological symptoms (including

---

\(^8\) Choosing Wisely Australia (n.d.)
\(^9\) Senate Community Affairs References Committee (2016a)
\(^10\) Senate Community Affairs References Committee (2016b)
\(^11\) TMS Consulting Pty Ltd (27 July 2018)
\(^12\) Allen + Clarke (2019)
\(^13\) Brown (2018)
\(^14\) Ibid.
Debilitating Symptom Complexes Attributed to Ticks (DSCATT) Clinical Pathway

3. DIFFERENTIAL DIAGNOSIS

3.1. Lyme disease

In Australia, Lyme disease should be considered in patients presenting with a travel history to Lyme disease endemic areas along with supporting symptoms and/or a known tick bite.\(^{16}\)

The information and recommendations on the diagnosis and management of Lyme disease in this Clinical Pathway include both Australian and international literature and guidelines. The most recently published evidence-based international guidelines for the diagnosis and management of Lyme disease included in the Clinical Pathway are the 2018 NICE Lyme disease guidelines and the 2019 Draft IDSA/AAN/ACR Lyme disease guidelines, both of which are underpinned by evidence-based reviews of the literature. The advice and recommendation from the 2019 IDSA/AAN/ACR Lyme disease guidelines are clearly marked ‘Draft’. If IDSA/AAN/ACR make any changes during finalisation of the guidelines, any such changes will be made to this Clinical Pathway.

While there are good overseas guidelines on Lyme disease, they may not all be applicable to the Australian context. If Lyme disease is suspected, consult with appropriate experts such as a consultant physician practising in his or her speciality of infectious disease or a specialist microbiologist. The recommendation to seek advice from an ID physician in Australia, where cases of overseas-acquired Lyme disease are very rare, is important. The difficulty in diagnosing Lyme disease, even in Lyme disease endemic areas, was highlighted in a systematic review that found that clinicians find it challenging to diagnose accurately due to the wide variation in symptoms; the infrequency with which they see the disease in practice; their level of confidence about being able to diagnose correctly; the ambiguity they experience about diagnostic tools; and their beliefs and behaviour relating to atypical or recurring symptoms.\(^{17}\)

Areas where Lyme disease is endemic internationally, clinical presentation of Lyme disease and special recommendations when considering a differential diagnosis of Lyme disease in a patient in Australia are covered in Sections 3.1.1 to 3.1.5.

Follow usual clinical practice to manage symptoms, such as analgesia for headaches or muscle pain, in patients being assessed for Lyme disease.\(^{18}\)

3.1.1. Transmission and geographical distribution of Lyme disease

Lyme disease is endemic in parts of the USA, Europe and Asia. A person visiting a Lyme disease endemic area may become infected with *Borrelia burgdorferi* sensu lato through a tick bite and subsequently develop Lyme disease. Overseas travellers to Lyme disease endemic areas may return to their home country before becoming symptomatic and/or being diagnosed.

Lyme disease is an infectious disease that can be transmitted to humans who are bitten by a tick carrying different species of *Borrelia* bacteria (spirochaetes) collectively known as *Borrelia*

\(^{15}\) Allen + Clarke (2019)
\(^{16}\) Department of Health (2018a)
\(^{17}\) Brunton et al. (2017)
\(^{18}\) NICE (2018a)
burgdorferi sensu latō,\textsuperscript{19, 20, 21, 22} In Lyme disease endemic areas, the risk of \textit{Borrelia} infection after the bite of an infected tick is low at only 1 per cent and 3 per cent in the United States and 3-12 per cent in Europe.\textsuperscript{23} The duration of tick attachment is one of the most important predictors of subsequent Lyme disease, with the risk of infection increasing the longer a tick is attached to the skin.\textsuperscript{24, 25, 26, 27} The incubation period is typically seven to fourteen days, but may be shorter, or longer (up to 30 days).\textsuperscript{28}

More than 18 spirochaete species comprise the \textit{B. burgdorferi} s.l. complex. Four species are found only in North America, eleven species occur in and are restricted to Eurasia and three species occur in North America and Europe.\textsuperscript{29}

The main species within this group include:\textsuperscript{30, 31}

- \textit{Borrelia burgdorferi} sensu stricto (North America, Europe)
- \textit{Borrelia afzelii} (in Europe, China), and
- \textit{Borrelia garinii} (in Europe, Asia).

Of the three main genospecies, \textit{B. garinii} and \textit{B. afzelii} are antigenically distinct from \textit{B. burgdorferi} s.s. which may account for the variation in clinical presentation in different geographic regions.\textsuperscript{32}

Less common species known to cause Lyme borreliosis include \textit{B. bavariensis} (in Europe), \textit{B. bissettiae} (United States, Europe), \textit{B. lusitaniae} (Europe), \textit{B. mayonii} (in mid-west USA), \textit{B. spielmanii} (Europe), \textit{B. valaisiana} (Europe, Asia).\textsuperscript{33}

Lyme disease is found in high rates in endemic areas, mainly the north east of the USA, some areas of Europe including the United Kingdom (UK) and some parts of Asia.\textsuperscript{34} Almost all confirmed cases of Lyme disease have occurred in the Northern Hemisphere.\textsuperscript{35} The majority of cases come from the United States and Europe (including the European part of Russia), with far fewer cases from Asia and some from North Africa.\textsuperscript{36}

In the United States, the Northeast, the mid-Atlantic region and the upper Midwest are the prime areas of endemicity and ten states (Connecticut, Delaware, Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island and Wisconsin) account for ≥93 per cent of annual cases.\textsuperscript{37}
In most of Europe, while Lyme disease is not a reportable disease and available data are less reliable, Lyme disease is highly endemic in much of Europe. The highest incidence is reported from southern Sweden, Lithuania, Germany, Austria, and Slovenia with the total number of annual cases in Europe estimated to be about three-fold higher than the number of cases reported to the Centers for Disease Control and Prevention (CDC).\textsuperscript{38} Infected ticks are found throughout the UK and Ireland, with particularly high risk areas being the South of England and the Scottish highlands.\textsuperscript{39}

**Transmission in pregnancy, sexual contact or blood products**

The Australian Government Department of Health advises that because there is no person-to-person transmission of classical Lyme disease, the risk to Australia and Australians is low.\textsuperscript{40}

An evidence-based review of person-to-person transmission of Lyme disease to inform the 2018 NICE Lyme disease guideline acknowledged that mother-to-baby transmission of Lyme disease is possible in theory. However, while there was an absence of evidence, the risk appears to be very low.\textsuperscript{41} The review included eight cohort studies, two case-control studies and two case series that reported outcomes related to vertical transmission (transmission of the pathogen directly from the mother to an embryo, fetus or baby during pregnancy or childbirth). Overall, the NICE guideline committee considered the evidence inconclusive in terms of identifying the risk of vertical transmission of Lyme disease and emphasised that there is a lack of good quality evidence in the area, but the risk appears to be very low. While the committee considered that vertical transmission is not impossible, no strong causal link between a maternal Lyme disease infection and adverse pregnancy outcomes could be found. As such, the guideline committee recommended that women diagnosed with Lyme disease during pregnancy follow the same clinical pathway as the rest of the population, except for choice of antibiotic treatment (using amoxicillin as first line rather than doxycycline) and an individual discussion about the potential risk of vertical transmission.\textsuperscript{42}

Additionally, NICE found no evidence for transmission of Lyme disease through sexual contact or blood products.\textsuperscript{43}

### 3.1.2. Clinical presentation of Lyme disease

Many people may not notice or remember a tick bite. Infection with *B. burgdorferi* s.l. can sometimes go unremarked, with mild symptoms that are ignored by the person. When symptoms occur, this is called Lyme disease.

A tick bite can be followed by an ‘erythema migrans’ rash (EM), a circular target-like rash which is considered pathognomonic for Lyme disease but can sometimes be mistaken for cellulitis or ringworm, delaying effective treatment. While the prevalence of EM is seen in about 70 per cent of the cases reported to the CDC, ≥90 per cent in cohorts of paediatric and adult US patients and in 70–95 per cent in European epidemiological studies, central clearing of EM is seen only in 19 per cent of US patients compared to almost 80 per cent of European patients,\textsuperscript{44} thus illustrating

\[\text{References:} \]

\textsuperscript{38} Borchers et al. (2015)  
\textsuperscript{39} NICE (2018a)  
\textsuperscript{40} Department of Health (2020)  
\textsuperscript{41} NICE (2018b)  
\textsuperscript{42} Ibid.  
\textsuperscript{43} Ibid.  
\textsuperscript{44} Borchers et al. (2015)
the variation in clinical manifestation according to where the infection was acquired and, therefore the need to take a travel history.

If there is no EM rash or it is unnoticed, diagnosis can be difficult as the same symptoms may be caused by many other conditions as well as Lyme disease.45

Lyme disease is customarily divided into three stages, with clinical manifestations varying in their occurrence and incidence depending on the infecting species and whether the infection was acquired in Eurasia or North America.46 Approximately 4–8 per cent of patients develop cardiac findings, 11 per cent develop neurologic findings and 40–60 per cent of patients manifest arthritis,47 although surveillance data over the past 15 years documents a much lower annual incidence of 30 per cent for Lyme arthritis in patients with untreated EM.48

45 NICE (2018a)
46 RCPA (2019)
47 Borchers et al. (2015)
48 Lantos et al. (2019)
Table 1: Stages of Lyme disease in patients who have travelled to Lyme disease endemic countries

**Early stage (Stage I)**

- Constitutional (flu-like) signs and symptoms including headache, myalgia, arthralgia and fever may be present.\(^{49}\)
- EM (usually around 7-14 days post-infected tick bite) either as a single expanding area, or a central spot surrounded by clear skin that is in turn encircled by an expanding red rash ('bull's-eye') which is centred on the tick bite is the characteristic sign of early infection in ≈80 per cent of patients.\(^{50}\)
- A rash, which is not EM, can develop as a reaction to a tick bite.\(^{51}\) This rash:
  - usually develops and recedes during 48 hours from the time of the tick bite
  - is more likely than EM to be hot, itchy or painful, and
  - may be caused by an inflammatory reaction, or infection with a common skin pathogen.

Other common causes of rashes that can be mistaken for EM include:

- reaction to an insect bite
- cellulitis
- tinea corporis (ringworm)
- granuloma annulare
- erythema multiforme (if multiple lesions), and
- nummular eczema.\(^{52}\)

**Early Dissemination (Stage II)**

- Early haematogenous dissemination to other sites
- Multiple EM lesions (≈20 per cent)
- Nervous system involvement (≈15 per cent) - headache, lymphocytic meningitis, mild neck stiffness, facial palsy
- Cardiac involvement (≈5 per cent) - acute onset of high-grade atrioventricular conduction defects, myopericarditis, and
- Joint involvement - a large joint oligoarthritis with brief attacks.\(^{53}\)

**Late Dissemination (Stage III)**

This stage can potentially occur after months to several years following the initial infection though the pathologic mechanism is unclear. It is hypothesised that any ongoing symptoms are more immune related which may or may not be a consequence to the initial infection. Ongoing infection remains a debatable diagnosis by the medical profession globally.

- ≈60 per cent present with rheumatologic involvement, intermittent attacks of joint swelling and pain in large joints, infiltration of mononuclear cells.
- ≈5 per cent present with neuroborreliosis, peripheral neuropathy, spinal radicular pain, distal paresthesia, encephalopathy leading to subtle cognitive disturbances, intrathecal antibody production and, rarely, cerebrospinal fluid pleocytosis.
- Acrodermatitis chronica atrophicans - a rare skin condition not seen in North American Lyme disease.\(^{54}\)

\(^{49}\) RCPA (2019)
\(^{50}\) Ibid.
\(^{51}\) NICE (2018a)
\(^{52}\) Public Health England (2018)
\(^{53}\) RCPA (2019)
\(^{54}\) Ibid.
3.1.3. Other presentations and considerations in diagnosing Lyme disease

Table 2: Other signs and symptoms of Lyme disease

In a patient with a history of travel to a Lyme disease endemic area, consider the possibility of Lyme disease in a patient presenting with several of the following symptoms as Lyme disease is a possible but uncommon cause of fever and sweats, swollen glands, malaise, fatigue, neck pain or stiffness, migratory joint or muscle aches and pains, cognitive impairment, such as memory problems and difficulty concentrating (‘brain fog’), headache and paraesthesia.

In a patient with a history of travel to a Lyme disease endemic area, consider the possibility of Lyme disease in a patient presenting with symptoms and signs relating to one or more organ symptoms (focal symptoms) as Lyme disease is a possible but uncommon cause of

- neurological symptoms (facial palsy, or other unexplained cranial nerve palsies, meningitis, mononeuritis multiplex or other unexplained radiculopathy) or rarely encephalitis, neuropsychiatric presentations or unexplained white matter changes on brain imaging)
- inflammatory arthritis affecting one or more joints that may be fluctuating and migratory
- cardiac problems such as heart block or pericarditis
- eye symptoms such as uveitis or keratitis, and
- skin rashes such as acrodermatitis chronica atrophicans or lymphocytoma.

Do not rule out the possibility of Lyme disease in people with symptoms but no clear history of tick bite.

Do not diagnose Lyme disease in people without symptoms, even if they have had a tick bite.

Be cautious about diagnosing Lyme disease in people without a supportive history or positive serological testing because of the risk of:

- missing an alternative diagnosis, and
- providing inappropriate management.

The most recent international guideline on Lyme disease - the IDSA/AAN/ACR 2019 Draft Lyme Disease Guidelines, suggested against routinely testing for Lyme disease in children presenting with developmental, behavioural or psychiatric disorders (weak recommendation; low quality evidence). In their systematic review to inform the draft Lyme disease guidelines the IDSA/AAN/ACR advised there are no data to support a causal link between tick-borne infections and childhood developmental delay or behavioural disorders (such as attention deficit hyperactivity disorder, autistic spectrum disorders, Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), learning disabilities, or psychiatric disorders). The IDSA/AAN/ACR noted that as with many acute medical illnesses, Lyme disease could worsen behavioural or psychiatric symptoms in children who are predisposed to these conditions. In addition, the IDSA/AAN/ACR also cautioned that because there is a low pre-test probability (prevalence) of Lyme disease in this population, broadly testing all such children will lead to a high proportion of false positive results, with misattribution of symptoms of Lyme disease leading to delays in care and unnecessary antibiotic exposure.

---

55 NICE (2018a)
56 Lantos et al. (2019)
57 Ibid.
3.1.4. **Situation in Australia in considering a differential diagnosis of Lyme disease**

Despite multiple studies which have thoroughly searched for it in Australian ticks and patients, the organisms that cause Lyme disease have not, to date, been identified in Australian ticks,68, 69, 70 nor any other vector that could transmit the disease to humans.71, 72 It is for this reason that the Australian medical profession does not support the diagnosis of locally acquired Lyme disease in Australia.73 While some Australians and healthcare providers believe that a form of ‘chronic Lyme disease’ exists, globally, ‘chronic Lyme disease’ is a disputed diagnosis which lacks sufficient supporting evidence.74, 75, 76, 77, 78, 79, 80

3.1.5. **Consult with appropriate Australian experts in infectious diseases**

In a country such as Australia where Lyme disease is not endemic and is not commonly seen in clinical practice, there are additional challenges in diagnosing Lyme disease. The Royal College of Pathologists of Australasia81 has published guidance on the diagnosis of Lyme disease specific to the Australian context. These guidance documents and the 2013 report by McKenzie82 stress that due to the non-specific nature of many clinical signs and symptoms the diagnosis of Lyme disease in non-endemic Australia cannot reliably be made on clinical signs and symptoms alone as many other infectious and non-infectious diseases can have similar features to Lyme disease. Laboratory testing is essential. A diagnosis of Lyme disease requires:83

- a careful medical history
- a history of overseas travel to areas where Lyme disease is endemic; a patient must have been exposed to ticks however, a history of documented tick bite is not essential as many tick bites go unnoticed
- objective clinical findings, and

---

58 Chalada et al. (2016)
59 Irwin et al. (2017)
60 Gofton, Doggett et al. (2015)
61 Gofton, Oskam et al. (2015)
62 Graves & Stenos (2017)
63 Mackenzie (2013)
64 Dehhaghi et al. (2019)
65 Department of Health (2018b)
66 Beaman (2016)
67 Loh et al. (2016)
68 Collignon et al. (2016)
69 Loh et al. (2017)
70 Harvey et al. (2019)
71 Department of Health (2018b)
72 Graves & Stenos (2017)
73 Department of Health (2018b)
74 Ibid.
75 NICE (2018a)
76 Wormser, et al. (2006)
77 Lantos et al. (2010)
78 Lantos et al. (2019)
79 Marzec et al. (2017)
80 Auwaeter et al. (2011)
81 RCPA (2019)
82 Mackenzie (2013)

---

Debilitating Symptom Complexes Attributed to Ticks (DSCATT) Clinical Pathway
appropriate in vitro diagnostic tests undertaken by National Association of Testing Authorities, Australia (NATA) and Royal College of Pathologists of Australasia (RCPA) accredited laboratories.

If Lyme disease is being considered, patients should be referred for Lyme disease serology to the GPs' regular Approved Pathology Practitioner (APP).

3.1.6. If EM rash is present and following appropriate expert advice, offer antibiotic treatment

For patients presenting with a bull's-eye rash (EM) and a relevant travel history, seek advice from a specialist microbiologist or an ID physician in regards to the appropriate investigations and treatments that are clinically relevant to the patient's presentation and commence antibiotic therapy.

While EM will resolve without antibiotic treatment, evidence indicates that currently used antibiotic regimens will effectively prevent the development of disseminated manifestations of Lyme disease (e.g. Lyme arthritis).  

A course of antibiotic treatment for Lyme disease should only be initiated based on the expert advice of either a consultant physician practising in his or her speciality of infectious disease or a specialist microbiologist.

See Section 6.1 for further detail.

3.2. Tick-borne disease known to be acquired in Australia

3.2.1. Suspect tick-borne disease if relevant symptoms but no overseas travel through a Lyme disease endemic area

In patients who have not travelled overseas AND who have or may have been recently bitten by a tick or in the past or who engage in activities such as bushwalking AND present with relevant acute or chronic symptoms suspect Australian tick-borne diseases (or Australian vector-borne diseases) and seek expert advice.

There are 17 human biting ticks known in Australia, but only six of these ticks are able to act as competent vectors for the transmission of pathogens to humans. Apart from the occasional local bacterial infection at the tick bite site (eschar) the only two systemic infections that are definitely known to be transmitted by tick bites in Australia are Rickettsial infections from infection with Rickettsia spp. (QTT, FISF, ASF) and Q fever (Coxiella burnetii).

The species of Australian ticks known to bite humans and transmit bacterial infection are:

- the paralysis tick (Ixodes holocyclus) is endemic on the east coast of Australia and
  - causes QTT due to R. australis
  - causes Q fever due to C. burnetii
- the common marsupial tick (Ixodes tasmani)
  - causes QTT due to R. australis

---

84 Lantos et al. (2019)
85 Dehhaghi et al. (2019)
86 Ibid.
87 Graves & Stenos (2017)
88 Mackenzie (2013)
89 Graves & Stenos (2017)
- causes ASF due to *R. honei* subsp. *marmionii*

- the **southern paralysis tick** (*Ixodes cornuatus*) causes QTT due to *R. australis*

- the **ornate kangaroo tick** (*Amblyomma triguttum*) occurs throughout much of the central, northern and western Australia and causes Q fever due to *C. burnetii*

- the **southern reptile tick** (*Bothriocroton hydrosauri*) occurs mainly in south-eastern Australia and causes FISF due to *R. honei*

- the **Haemaphysalis novoaeguinae** (no common name) causes ASF due to *R. honei* subsp. *marmionii*.

### 3.2.2. Diagnosis of tick-borne disease known to exist in Australia is challenging

The signs and symptoms of Rickettsial infections in Australia include eschar, fatigue, fever, headache, myalgia and rash (macular, papular, vesicular) although the severity and duration of Rickettsial diseases vary considerably. QTT and ASF have similar core clinical manifestations with a range of other symptoms observed. Early clinical features are often non-specific, making diagnosis challenging. Additionally, symptoms may overlap with other infectious diseases including those that are transmitted by non-tick vectors as well as a number of chronic diseases. Seek further expert advice from appropriate experts in vector-borne diseases as necessary.

Seek further expert opinion as necessary depending upon the nature of the patient’s clinical presentation from appropriate experts in vector-borne diseases including specialist microbiologists with diagnostic experience and ID physicians for diagnosis and treatment of vector-borne diseases.

### 3.2.3. Queensland Tick Typhus (QTT)

Queensland Tick Typhus (QTT) is an emerging public health threat and an increasingly recognised important cause of community-acquired acute febrile illness in Eastern Australia. Diagnosing *R. australis* infection can be challenging and in patients presenting with fever and a rash, epidemiologic data and knowledge of high-risk exposure activities can be valuable in considering QTT. A high degree of suspicion is required as the nonspecific symptoms in early QTT can lead to a delay in diagnosis. Early recognition and treatment is therefore important.

**Transmission and geographic distribution**

QTT is regularly seen on the east coast of Australia from the Torres Strait Islands to the southern corner of Victoria, with the northern suburbs of Sydney a very common location for transmission of this infection. In north-eastern New South Wales, 15.4 per cent of paralysis ticks (*Ixodes holocyclus*) were found to contain *R. australis*, suggesting a one in six risk of being...
infected with the rickettsia if bitten by this tick in this location.\textsuperscript{98, 99} The geographical distribution of the known human pathogen that causes QTT fever (\textit{R. australis}) is expanding due to changes in climate and human population demographics.\textsuperscript{100}

Infection by \textit{R. australis} may occur throughout the year in immunocompetent people of all ages and ethnicities although 80 per cent of documented cases have occurred in winter and spring (June to November) coinciding with increased tick densities in these months.\textsuperscript{102}

\textbf{Clinical signs and symptoms}

In symptomatic infections, QTT is often a mild condition involving fever, headache, malaise, myalgia, a rash, eschar and enlarged lymph nodes.\textsuperscript{103, 104, 105} QTT may, however, be severe or fatal and may have unusual features.\textsuperscript{106} Less common manifestations of QTT include arthralgia, splenomegaly, abdominal pain, dry cough, sore throat, conjunctivitis and photophobia.\textsuperscript{107} While QTT is not known to directly affect the central nervous system, there have been reports of
confusion, seizures and hallucinations as a prominent feature of this disease. There are no known identified risk factors for developing severe disease or complications of QTT.

**Fever:** High grade fever of up to 41 °C is observed in acute cases. Prolonged fever is associated with rickettsaemia, end organ dysfunction and intensive care admissions.

**Rash:** Rash morphology is variable, and can be macular, maculopapular, vesicular or pustular, with the latter two forms sometimes confused with acute varicella. Infrequently the rash is pruritic. The rash usually lasts for 10–12 days, can appear as early as 24 hours after a tick bite and typically follows a widespread, global eruption involving the trunk and limbs. EM at and around the *Ixodes* attachment site is not uncommon in QTT. Of note, EM is observed in other tick-borne illnesses such as *Rickettsia* and *Borrelia* spp. including Lyme disease, hence the recommendation to seek advice from appropriate experts in vector-borne diseases.

In approximately 50–65 per cent of *R. australis* infections, an eschar is seen, with the detection of an eschar being diagnostically valuable. It is, however, often difficult to find as it can occur in sites that can be missed on examination such as in the axilla or groin. Tender lymphadenopathy, usually localised to the region draining the tick bite or eschar occurs in approximately 70 per cent of patients.

The clinical presentation of a case of QTT in rural Queensland published by Royal Australian College of General Practitioners (RACGP) provides advice to support GPs.

While post-infection fatigue, a well-known consequence of several infections including Ross River virus, Q fever and Epstein-Barr virus, is not yet widely recognised as a problem following Rickettsial infection, it has been suggested by a study involving two large cohorts of fatigued and non-fatigued patients and a case report.

### 3.2.4. If QTT suspected, following advice from appropriate experts, start antibiotic therapy (see Therapeutic Guidelines: Antibiotic)

Early recognition and treatment is important in QTT. Early initiation of doxycycline is critical as a delay in appropriate antimicrobial therapy is associated with increased likelihood of progression to severe disease and complications. Patients usually show marked clinical improvement after 48 hours of starting antimicrobial therapy. See Section 6.2 for further detail on initial management.
3.2.5. Australian Spotted Fever (ASF)

**Geographical distribution**

Australian Spotted Fever (ASF) has been reported in the eastern half of Australia and occurs in subtropical and tropical areas of Queensland extending down the east coast to East Gippsland in Victoria.\(^{118, 119, 120}\)

Figure 2: Distribution of Australian Spotted Fever\(^{121}\)

![Map of Australia showing distribution of Australian Spotted Fever](image)

**Clinical presentation**

Symptoms of ASF include fever, headache and muscle aches with a stiff neck, vomiting and mental confusion also being possible.\(^{122}\)

3.2.6. Flinders Island Spotted Fever (FISF)

**Geographical distribution**

Flinders Island Spotted Fever (FISF) is transmitted by the tick *Bothriocroton hydrosauri* and has been reported in Flinders Island, mainland Tasmania, Southern-eastern Australia, south-western coastal areas of Western Australia in Salisbury Island and Walpole, and south-eastern coastal regions of South Australia near Adelaide.\(^{123, 124, 125}\)

---

\(^{118}\) Dehhaghi et al. (2019)  
\(^{119}\) Graves & Stenos (2017)  
\(^{120}\) Chalada et al. (2016)  
\(^{121}\) Graves (n.d.)  
\(^{122}\) Banks & Hughes (2012)  
\(^{123}\) Dehhaghi et al. (2019)  
\(^{124}\) Graves & Stenos (2017)  
\(^{125}\) Willis et al. (2019)
The Department of Health, Tasmania, reported in 2019 that confirmed cases of FISF have been acquired in Tasmania, including in the Midlands of Tasmania.127

**Clinical presentation**

Symptoms of FISF include cough, fever, headache, maculopapular rash, myalgia and arthralgia.128

3.2.7. **Q fever**

In Australia, Q fever is a nationally notifiable disease, with a Q fever laboratory case definition129 and is included in the Communicable Diseases Network Australia (CDNA) National Guidelines for Public Health Units.130 In Australia, Q fever is the most commonly reported zoonotic disease,131 As Q fever can be mistaken for other conditions, including other zoonotic diseases (e.g. leptospirosis, brucellosis), the work up should be determined by a detailed history, examination and initial screening investigation, with a useful algorithm having been developed for GPs.132

**Transmission and geographical distribution**

Q fever is acquired via various modes of transmission, a minority of which is tick-borne. While *Coxiella burnetii* are present in both the paralysis tick and ornate kangaroo tick, and therefore it is classified as a tick-borne disease, most cases of Q fever infection occur by inhalation of infectious aerosols from carrier (reservoir) vertebrate animals such as goats, sheep cattle, kangaroos and

---

126 Graves (n.d.)
127 Willis et al. (2019)
128 Dehhaghi et al. (2019)
129 Public Health Laboratory Network (2017)
130 CDNA (2018)
131 Eastwood et al. (2018)
132 Ibid.
domestic pets or dust particles\textsuperscript{133, 134, 135, 136} contaminated by birth fluids, faeces or urine from infected animals. Rats may also harbour the tick \textit{Amblyomma triguttum} which is a natural host for the \textit{Coxiella burnetii} bacterium that causes Q fever in humans. The organism can remain dormant in soil and dust and spread by vehicle movements and activities such as lawn mowing or spread over wide areas under the influence of the wind and result in disease outbreaks.\textsuperscript{137} The incubation period is typically 2–3 weeks; person to person spread rarely occurs.\textsuperscript{138} Persons at increased risk of Q fever are:

- at risk occupational groups with contact of high risk animal products, including (but not limited to): abattoir and meat workers; agriculture, livestock and dairy farmers/workers; laundry workers handling clothes of at-risk workplaces; veterinary professionals and staff; animal shooters/hunters; dog/cat breeders and anyone regularly exposed to parturient animals
- other people through non-occupational, environmental exposures including (but not limited to): family members of occupationally exposed groups; people living in close proximity to a high risk industry (neighbouring livestock farms and stockyards); visitors to at risk environments; people involved in mowing which aerosolises dust potentially contaminated by animal excreta, and
- persons at increased risk for chronic Q fever after experiencing an acute infection including: immunosuppressed persons; pregnant women; persons with valvular heart disease/valvular prosthesis; persons with aneurysms/vascular grafts.\textsuperscript{139}

In 2016, there were 551 cases (2.3 per 100,000 population) in the annual Q fever notification. The majority of Australian Q fever notifications were reported from Queensland and New South Wales during 2011–2015, with the notification rate remaining highest in south west/central west Queensland and northwest New South Wales, and generally reflecting the intensity of local cattle, sheep, and goat husbandry, and associated processing industries,\textsuperscript{140} although it is emerging in other regions, including the Northern Territory and southwest Western Australia.\textsuperscript{141}

\textbf{Clinical presentation}

Q fever may present as an acute or chronic illness, with the majority (60 per cent) of cases with asymptomatic/subclinical presentations.\textsuperscript{142, 143} People who do become sick often have a severe flu-like illness.

\textit{Acute Q fever}

The most common manifestation is an influenza-like illness which might occur in conjunction with abnormal liver function tests, hepatitis and/or pneumonia. It can appear similar to other aetiologies of atypical pneumonia, such as those associated with \textit{Legionella} or \textit{Mycoplasma}, requiring consideration of differential diagnoses. Commonly reported signs and symptoms

\begin{itemize}
  \item \textsuperscript{133} Dehhaghi et al. (2019)
  \item \textsuperscript{134} McKenzie (2013)
  \item \textsuperscript{135} Graves & Stenos (2017)
  \item \textsuperscript{136} CDNA (2018)
  \item \textsuperscript{137} Eastwood et al. (2018)
  \item \textsuperscript{138} CDNA (2018)
  \item \textsuperscript{139} Ibid.
  \item \textsuperscript{140} Ibid.
  \item \textsuperscript{141} Dehhaghi et al. (2019)
  \item \textsuperscript{142} CDNA (2018)
  \item \textsuperscript{143} Chalada et al. (2016)
\end{itemize}
include fever, chills, sweats, severe headache, (especially behind the eyes), photophobia, weakness, anorexia, nausea, myalgia, cough and weight loss.\textsuperscript{144, 145} The most prevalent acute symptoms are fever (95 per cent), headaches (53 per cent) and myalgia (38 per cent).\textsuperscript{146}

In a minority of infected cases (≤1 per cent), patients may develop pericarditis, myocarditis or neurologic complications (e.g. meningoencephalitis, encephalomyelitis).\textsuperscript{147} Unlike Rickettsial infections (see above), Q fever is unlikely to be associated with a rash.\textsuperscript{148}

\textit{Chronic Q fever}

Chronic Q fever is the most serious form of the disease and can occur from one month to several years after acute illness as a result of persistence of \textit{C. burnetii} infection in the host after primary infection.\textsuperscript{149, 150} Sometimes there is no history of acute illness. Chronic Q fever may present as one of three forms according to the focus of infection: endocarditis; osteoarticular infections; and vascular infections with the abdominal or thoracic aorta the most frequent site for vascular infections.\textsuperscript{151} Chronic Q fever may also manifest as chronic hepatitis, pericarditis, and very rarely as adenopathies, lung or splenic pseudotumours, or chronic neuropathy.\textsuperscript{152} As such, Q fever may sometimes present as an infection similar to Lyme carditis or Lyme neuroborreliosis.\textsuperscript{153}

\textit{Q fever fatigue syndrome}

Q fever fatigue syndrome (QFS) refers to systemic symptoms that fail to recover more than 12 months after acute illness and is the most common sequela following acute infection in Australia, occurring in approximately 10–15 per cent of patients. The initial infection may be mild or severe, and patients present with a ‘chronic fatigue-like’ picture.\textsuperscript{154} Typical features include: profound fatigue, arthralgia, myalgia, concentration and memory problems, sleeping problems, sweats and headaches.\textsuperscript{155} Alcohol intolerance is a commonly reported feature.\textsuperscript{156} The severity of the initial acute infection is the only known risk factor for the development of the post-Q-fever fatigue.\textsuperscript{157}

\textsuperscript{144} Eastwood et al. (2018)
\textsuperscript{145} CDNA (2018)
\textsuperscript{146} Chalada et al. (2016)
\textsuperscript{147} CDNA (2018)
\textsuperscript{148} Dehhaghi et al. (2019)
\textsuperscript{149} CDNA (2018)
\textsuperscript{150} Eastwood et al. (2018)
\textsuperscript{151} CDNA (2018)
\textsuperscript{152} Chalada et al. (2016)
\textsuperscript{153} Ibid.
\textsuperscript{154} Eastwood et al. (2018)
\textsuperscript{155} CDNA (2018)
\textsuperscript{156} Eastwood et al. (2018)
\textsuperscript{157} Ibid.
3.2.8. If Q fever suspected clinically (appropriate symptoms AND at high risk epidemiologically), commence empirical treatment while waiting for laboratory tests

While achieving a timely, definitive diagnosis of Q fever is challenging, early treatment is beneficial and empirical antibiotic therapy should be considered if the presentation and clinical history suggest a zoonotic disease.\textsuperscript{158} Moreover, the Q fever CDNA guidelines for Public Health Units specify that if Q fever is suspected clinically (in people with appropriate symptoms AND who are at high risk of contracting Q fever), empirical treatment should be commenced without waiting for laboratory tests.\textsuperscript{159} Refer to \textit{Therapeutic Guidelines: Antibiotic} and Section 6.2 for further detail.

3.3. Patients presenting with persistent debilitating symptoms and no diagnosis

3.3.1. If tick-borne disease is not suspected, consider alternative diagnoses

Take care to identify any potentially treatable illness.

The identification of MUS, including identification of the symptom complex associated with DSCATT, is one of exclusion and requires ongoing review as new symptoms arise or treatments are trialled. A full history and examination are critical.

A clue to the underlying cause may be found in the particular symptom cluster, time course of symptoms, family history, social history, medications, travel or occupation.

Develop a differential diagnosis with consideration of the following causes:

- infectious – including blood-borne or sexually transmitted infections, vector-borne diseases, travel related, food and water-borne
- autoimmune – including inflammatory arthritis, motor neurone disease, multiple sclerosis
- neoplastic
- psychological – including depression, anxiety and reactions to traumatic events
- inflammatory
- vascular
- neurological
- cardio-respiratory
- lifestyle related – including diet, exercise, sleep and stress.

\textsuperscript{158} Eastwood et al. (2018)
\textsuperscript{159} CDNA (2018)
4. DIAGNOSTIC TESTING

4.1. Lyme disease

4.1.1. Refer for laboratory testing for Lyme disease using a two-tier serology test in a NATA/RCPA accredited laboratory

There is established Australian guidance for diagnostic laboratory testing for Lyme disease.\textsuperscript{160} Diagnostic testing for Lyme disease should only be initiated following advice from appropriate experts such as a consultant physician practising in his or her speciality of infectious diseases or a specialist microbiologist and should only be undertaken in Australia in a pathology laboratory accredited by NATA/RCPA to conduct such testing. If Lyme disease is being considered, patients should be referred for Lyme disease serology to your regular Approved Pathology Practitioner (APP).

\textit{NATA/RCPA Accreditation and Accredited Laboratories}

It is essential to use NATA/RCPA-accredited, internationally recognised laboratories for diagnostic testing. NATA accreditation provides a means of determining, formally recognising and promoting that an organisation is competent to perform testing, inspection, calibration, and other related activities. Accreditation delivers confidence and underpins the quality of results. NATA's accreditation is based on a peer-review process and is based on international standards. Since NATA accreditation is highly regarded both nationally and internationally as a reliable indicator of technical competence, use of the NATA logo and use of a NATA endorsement on reports tells prospective and current clients that the facility has been assessed against best international practice.\textsuperscript{161}

Additionally, RCPA notes Australia leads the world in laboratory accreditation and advises all pathology laboratories in Australia receiving funding via Medicare must be accredited by the NATA/RCPA Laboratory Accreditation Program. The Standards are set by the National Pathology Accreditation Advisory Council (NPAAC). The quality management aspects of the NPAAC requirements are based on the international standard ISO 15189 Standard for Medical Laboratories.\textsuperscript{162}

NATA/RCPA Accredited Laboratories can detect tick-borne illnesses.

\textit{NATA/RCPA accredited laboratories follow international best practice in diagnostic testing for Lyme disease}

The current standard laboratory protocol for diagnosing Lyme disease in Australian diagnostic laboratories follows international best practice and uses a two-tier serology system, the first stage involving screening with an enzyme-linked immunosorbent assay (ELISA) and, if positive, followed by an immunoblot assay (Western blot).

In Australia, the National Serology Reference Laboratory (NRL) review of serological assays to diagnose Lyme disease determined the tests used by accredited laboratories to diagnose Lyme

\textsuperscript{160} RCPA (2019)
\textsuperscript{161} National Association of Testing Authorities (NATA) (n.d.) A database of NATA accredited facilities can be found at: https://www.nata.com.au/accredited-facility.
\textsuperscript{162} Royal College of Pathologists of Australasia (RCPA) (n.d.)
disease had equivalent reliability to tests used in overseas laboratories.\textsuperscript{163} This therefore means Australian NATA/RCPA accredited laboratories are able to confidently diagnose classical Lyme disease acquired in patients who have travelled to endemic areas\textsuperscript{164} and have contracted the infection more than four weeks prior to testing, noting that most patients seroconvert within four to eight weeks of infection.\textsuperscript{165} A follow up paper to the NRL report noted that in the known negative population, specificities of the immunoassays ranged between 87.7 per cent and 99.7 per cent, and in Australia’s low prevalence population this would translate to a positive predictive value of <4 per cent.\textsuperscript{166}

While the NRL report confirmed that Australian laboratories have equivalent reliability to tests used in overseas laboratories, tests for Lyme disease have limitations whether internationally or in Australia (see Section 4.1.2). Note that diagnostic tests conducted overseas are not covered under Australia’s Medicare arrangements.

Some people believe that they have acquired Lyme disease in Australia because the results of screening antibody tests to \textit{B. burgdorferi} are positive. However, where a patient has not travelled overseas, these positives are all likely to be false positive test results. All diagnostic tests produce both false positive and false negative results. The frequency depends on the specificity and sensitivity of the test and the prevalence of the disease in the population. Even a highly specific test will produce some false positives, so that people who have never been exposed to \textit{B. burgdorferi} can have reactive antibody results.\textsuperscript{167}

\textit{Laboratory testing is essential to diagnose Lyme disease in Australia}

Despite multiple studies which have thoroughly searched for it in Australian ticks and patients, the organisms that cause Lyme disease have not, to date, been identified in Australia. This means that Australia is a non-endemic country for Lyme disease, and it is not possible to reliably diagnose Lyme disease on clinical symptoms and signs alone. Laboratory testing is essential, as many other infectious and non-infectious diseases can have similar features to Lyme disease and all stages of Lyme disease have features that mimic other medical conditions.\textsuperscript{168}

Infection with \textit{B. burgdorferi} s.l. leads initially to an IgM antibody response, followed two weeks later by an IgG antibody response. The IgM response tends to be relatively short-lived in most patients, but the IgG remains for decades following infection.\textsuperscript{169}

In a 2019 review of European and American guidelines (16 guidelines from seven countries) for the diagnosis of Lyme disease, all guidelines indicated that the diagnosis of Lyme disease is currently based on a two-tier serology at all stages of infection, except for the early localised dermatological presentation known as EM.\textsuperscript{170} While the recommendation from 15 of the 16 international guidelines was no serology testing in the case of EM suspicion due to early serology not being sensitive enough (40 per cent to 60 per cent) to confirm Lyme diagnosis at the EM stage,\textsuperscript{171} in Australia, where Lyme disease in not endemic diagnostic testing is recommended.

\textsuperscript{163} National Serology Reference Laboratory (NRL) (2017)
\textsuperscript{164} RCPA (2019)
\textsuperscript{165} Ibid.
\textsuperscript{166} Best et al. (2019)
\textsuperscript{167} Collignon et al. (2016)
\textsuperscript{168} RCPA (2019)
\textsuperscript{169} Mackenzie (2013)
\textsuperscript{170} Eldin et al. (2019)
\textsuperscript{171} Ibid.
In Australia, laboratory diagnostic testing for Lyme disease is required for two reasons:

1. Unless the clinician is familiar with the pathognomonic EM rash, it is clinically safer to obtain supportive evidence of infection through diagnostic testing (culture or Polymerised Chain Reaction (PCR) of the tissue or more usually antibody testing on a convalescent sample).

2. Diagnostic laboratory support is preferred for patients presenting with non-specific signs and symptoms of a disease syndrome, notwithstanding the limitations of the tests.

### 4.1.2. Provide advice to patients about the tests for Lyme disease

It should be noted that currently available tests for Lyme disease carry limitations. The interpretation of serological assays in Lyme disease requires an understanding of the clinical indications and limitations of the tests, and the usefulness of serological tests for Lyme disease depends on the pre-test probability and subsequent predicative values in the setting where the tests are being used.\(^\text{172}\)

While both the IDSA/AAN/ACR and NICE identify that the currently available protocol is reliable when used appropriately, both also note the limitations of the testing protocol.\(^\text{173, 174}\)

NICE recommends clinicians provide the following information to patients being tested for Lyme disease:\(^\text{175}\)

- tests for Lyme disease have limitations and that false-positive and false-negative results can occur and what this means
- most tests for Lyme disease assess for the presence of antibodies and the possible reduction of accuracy of the test if:
  - testing is carried out too early (before antibodies have developed), and
  - the person has reduced immunity, for example, in people on immunosuppressant treatments, which might affect the development of antibodies
- the symptoms and signs associated with Lyme disease overlap with those of other conditions
- they will be assessed for alternative diagnoses if their tests are negative and their symptoms have not resolved, and
- symptoms such as tiredness, headache and muscle pain are common, and a specific medical cause is often not found.

In 2019, IDSA/AAN/ACR advised in their draft Lyme disease guidelines:\(^\text{176}\)

- serologic (serum antibody) testing is highly sensitive in patients with non-cutaneous manifestations of Lyme disease, as these manifestations typically develop after weeks to months of infection
- serologic testing is also highly specific when performed and interpreted according to current guidelines

---

\(^{172}\) Leeflang et al. (2016)

\(^{173}\) Lantos et al. (2019)

\(^{174}\) NICE (April 2018a)

\(^{175}\) Ibid.

\(^{176}\) Lantos et al. (2019)
predictive value is increased when results are correlated with clinical features, patient history and risk factors, and
currently, the only Food and Drug Administration (FDA) cleared or approved diagnostic assays for Lyme disease are antibody tests.

4.1.3. **Commercially available laboratory testing methods to be avoided**

Measurement of CD57 lymphocytes (by flow cytometry) and PCR for Lyme disease on urine samples is not recommended in the laboratory diagnosis of Lyme disease in Australian laboratories.\(^{177}\) IDSA/AAN/ACR\(^{178}\) concurred in 2019, advising that some commercially available laboratory testing methods including non-standard serology interpretation, urine antigen or DNA testing, or the use of lymphocyte transformation test or a quantitative CD57 lymphocyte assay should be avoided for clinical use due to lack of systematic, independent, reproducible validation studies.

Likewise, current guidance from the CDC on laboratory tests that are not recommended for Lyme disease due to the accuracy and clinical usefulness not having been adequately established is similar to those highlighted by IDSA/AAN/ACR and Australian laboratory guidance. Examples of tests that are not recommended by the CDC include:\(^{179}\)

- capture assays for antigens in urine
- culture, immunofluorescence staining, or cell sorting of cell wall-deficient or cystic forms of *B. burgdorferi*
- lymphocyte transformation tests
- quantitative CD57 lymphocyte assays
- “Reverse Western blots”
- in-house criteria for interpretation of immunoblots
- measurements of antibodies in joint fluid (synovial fluid), and
- IgM or IgG tests without previous ELISA/EIA/IFA.

4.2. **Tick-borne disease known to be acquired in Australia**

4.2.1. **Refer for testing for known Australian tick-borne diseases**

For patients presenting with tick bite and systemic symptoms (e.g. fever) consult with an appropriate expert in tick-borne diseases such as a specialist microbiologist with diagnostic expertise or an ID physician for appropriate test referral and follow advice for requests for testing for known Australian tick-borne infections and treatment of infections found. If the results do not show arthropod-borne infection, consider an alternative diagnosis.

It is important to note that DSCATT is a term used to describe a symptom complex with the symptoms often attributed to a tick bite. DSCATT is not a diagnosable disease. As such, there is no diagnostic test to diagnose DSCATT.

\(^{177}\) RCPA (2019)
\(^{178}\) Lantos et al. (2019)
\(^{179}\) Centers for Disease Control and Prevention (CDC) (2018)
Further information on the tests for known Australian tick-borne diseases is available on the Australian Rickettsial References Laboratory website.\(^{180}\)

**Queensland Tick Typhus (QTT)**

Serological assays remain the main diagnostic test modality for diagnosing Rickettsial infections. Currently, the indirect microimmunofluorescence assay (IFA) is considered the gold standard assay for diagnosing QTT. Acute and convalescent serum samples are taken 10-14 days apart and a four-fold rise in SFG antibody titre or a single positive titre of 1:256 is used to indicate acute or recent infection.\(^{181}\)

See also Update on Rickettsial infections.\(^{182}\)

**Australian Spotted Fever**

See Update on Rickettsial infections.\(^{183}\)

**Flinders Island Spotted Fever**

See Update on Rickettsial infections.\(^{184}\)

**Q fever**

The Q fever National Guidelines for Public Health Units developed by CDNA specify that, if acute Q fever infection is suspected, a series of blood specimens should be requested and should include:

- unclotted blood or serum for Q fever PCR (and possible culture); AND
- paired (acute and convalescent) serum/clotted blood specimens taken 2-3 weeks apart for serology.

The collection of convalescent sera from all cases is critical, even if the patient has since recovered. See Q fever CDNA National Guidelines for Public Health Units Section 8 Laboratory testing for specific detail.\(^{185}\)

### 4.3. Patient presenting with persistent debilitating symptoms and no diagnosis

Investigations should be underpinned by clinical evidence. International evidence indicates patients with MUS are at risk of potentially harmful additional testing and are often subjected to repeated diagnostic investigations, and unnecessary and costly referrals and interventions. Unnecessary investigations that do not show anything are often not reassuring. They can make someone worry that there is something still to be found and more tests are needed.

For fatigue, diagnostic testing is determined by the differential diagnosis as per normal clinical practice.\(^{186}\)

---

\(^{180}\) Australian Rickettsial Reference Laboratory (n.d.)
\(^{181}\) Stewart et al. (2017)
\(^{182}\) Graves (n.d.)
\(^{183}\) Ibid.
\(^{184}\) Ibid.
\(^{185}\) CDNA (2018)
\(^{186}\) Murtagh (2003)
5. **DIAGNOSIS**

5.1. **Lyme disease**

Lyme disease is not a notifiable disease in Australia.

5.1.1. **Confirmed diagnosis**

A confirmed case of Lyme disease in Australia requires laboratory evidence AND clinical evidence AND epidemiological evidence.

The Royal College of Pathologists of Australasia notes that caution is important in dealing with specimens for Lyme disease testing and in interpreting of positive or indeterminate laboratory results and advises that medical microbiologists should add explanatory comments to all such reports to assist the referring doctor to interpret the laboratory findings correctly.\(^\text{187}\)

In addition to the sensitivity and specificity of the diagnostic tests recommended in international guidelines for Lyme disease, the prevalence of the disease or the pre-test probability of a disease strongly influences interpretation of any diagnostic test result. In a region where Lyme disease is uncommon, patients with highly characteristic clinical presentations are rarely found to have Lyme disease and positive test results are seldom associated with clinically probable infection, although the negative predictive value of Lyme disease testing will be very high.\(^\text{188}\) In an area of low Lyme disease incidence in the United States, a study of Lyme disease testing showed an 80 per cent false-positive rate which puts patients at risk of incorrect Lyme disease diagnosis and adverse drug reactions from inappropriate treatment.\(^\text{189}\) Therefore, awareness of epidemiological context and the absence of an alternative diagnosis are necessary for a clinician to decide whether a positive test is explanatory or coincidental. The difficulties in interpreting diagnostic tests for Lyme disease as described above, coupled with the difficulties clinicians in Lyme disease endemic countries experience in diagnosing Lyme disease\(^\text{190}\) underpin the recommendation that medical professionals seek advice from appropriate experts in infectious diseases or pathology.

5.1.2. **No confirmed diagnosis of Lyme disease and symptoms resolve**

If the immunoblot test for Lyme disease is negative and symptoms have resolved, explain to the patient that no treatment is required.\(^\text{191}\)

5.1.3. **No confirmed diagnosis of Lyme disease and symptoms persist**

If the immunoblot test for Lyme disease is negative (regardless of the ELISA result) but symptoms persist, NICE recommends considering a discussion with, or referral to, a specialist appropriate to the patient's history and symptoms (e.g. adult or paediatric specialist microbiologist or ID physician, rheumatologist or neurologist) to:\(^\text{192}\)

- review whether further testing may be required for suspected Lyme disease (e.g. synovial fluid aspirate, or biopsy, or lumbar puncture for cerebrospinal fluid analysis), OR

\(^{187}\) RCPA (2019)
\(^{188}\) Lantos et al. (2015a)
\(^{189}\) Ibid.
\(^{190}\) Brunton et al. (2017)
\(^{191}\) NICE (2018a)
\(^{192}\) Ibid.
consider alternative diagnoses including both infectious (including other tick-borne diseases) and non-infectious diseases.

5.2. Tick-borne diseases known to be acquired in Australia

Queensland Tick Typhus

For diagnosis of QTT, laboratory investigations of cases include:\(^{193}\)

- mild-to-moderate thrombocytopenia commonly early in the disease course transforming into a reactive thrombocytosis during recovery from the disease
- a transient and mild elevation of hepatic transaminases early in the disease
- leukopenia in mild cases
- neutrophilia and toxic changes on blood film in patients presenting with severe infection, and
- significantly raised C-reactive protein measurements in systemic Rickettsial infection in contrast to uncomplicated viral infections.

A number of factors can complicate the diagnosis:\(^{194}\)

- substantial cross-reactivity of antibodies can occur between some rickettsia and with other species of bacteria such as Proteus and Legionella
- concomitant illnesses such as rheumatologic- and immune-mediated disorders can yield false-positive Rickettsial serological tests
- occasionally, patients infected with \(R. australis\) do not seroconvert, and
- serology tests can be difficult to interpret in acute illness; low level titres are associated with previous SFG \(Rickettsia\) exposure and to a patient's current non-Rickettsial infection.

Initial negative serological studies do not rule out Rickettsial infection and should not alter treatment completion in potentially infected patients.\(^{195}\)

See also Update on Australian Rickettsial Infections.\(^{196}\)

Australian Spotted Fever

See Update on Australian Rickettsial Infections.\(^{197}\)

Flinders Island Spotted Fever

See Update on Australian Rickettsial Infections.\(^{198}\)

---

\(^{193}\) Stewart et al. (2017)

\(^{194}\) Ibid.

\(^{195}\) Thomas & Wu (2018)

\(^{196}\) Graves (n.d.)

\(^{197}\) Ibid.

\(^{198}\) Ibid.
Q fever

Diagnosis of Q fever can be made by a medical professional based on symptoms, clinical examination, and laboratory tests on blood samples. Two or more blood samples on separate occasions are often required to confirm a Q fever diagnosis.\textsuperscript{199}

CDNA provide details on laboratory tests (PCR and serology testing) and interpreting results for Q fever.\textsuperscript{200}

Advice by RACGP to assist GPs in diagnosing Q fever, including in aspects of diagnostic tests is also available.\textsuperscript{201}

5.3. Patient presenting with persistent debilitating symptoms - diagnosis of specific disease(s) is established

Where a specific disease or diseases are diagnosed, with or without specialist input, treat accordingly, as per usual clinical practice. When symptoms resolve, the patient exits this DSCATT Clinical Pathway.

5.4. Patient presenting with persistent debilitating symptoms - no diagnosis is established and medically unexplained symptoms persist

If no diagnosis of a specific disease(s) is established through this phase of the pathway and symptoms persist, move to next phase, the stepped care approach.

People with medically unexplained symptoms may obtain a diagnosis over time as symptoms develop and guide to the origin of the illness. Others may find that symptoms resolve over time without ever identifying a cause.

\textsuperscript{199} CDNA (2018)
\textsuperscript{200} Ibid.
\textsuperscript{201} Eastwood et al. (2018)
6. INITIAL MANAGEMENT

6.1. Lyme disease

6.1.1. International guidelines for the treatment of Lyme disease

Lyme disease is treated with antimicrobials from several classes with activity against *B. burgdorferi*, including doxycycline, penicillin, amoxicillin, cefuroxime, ceftriaxone and azithromycin, with the goals of treatment being the resolution of objective signs and symptoms of infection with prevention of relapsed active infection or new complications of infection. Under most circumstances, oral therapy is effective and preferred over intravenous therapy due to equivalent efficacies, tolerability, and cost.\(^{202}\)

Treatment recommendations, based on available randomised controlled trials (RCTs) published by American professional bodies such as the IDSA, the American Academy of Paediatrics and a variety of national and supranational associations in Europe (EUCLAB) indicate that the approaches to therapy are largely similar on both sides of the Atlantic with some minor differences in the recommended dosage and treatment duration.\(^{203}\)

The majority of international guidelines, including IDSA\(^{204}, 205\) NICE\(^{206}\) and IDSA/AAN/ACR\(^{207}\) recommend one course of antibiotic therapy for all presentations of Lyme disease.

The NICE guideline covers diagnosing and managing Lyme disease, and aims to raise awareness of Lyme disease should it be suspected, and ensure people have prompt and consistent diagnosis and treatment. The recommendations aim to standardise antibiotic treatment and to provide a consistent framework for good practice in managing Lyme disease.\(^{208}\)

The latest guidelines from NICE (2018) recommend antibiotic therapy of 21 days for all presentations except Lyme arthritis (28 days).

The 2018 NICE guidelines were underpinned by the following evidence-based reviews:

- Management of erythema migrans\(^{209}\)
- Management of non-specific symptoms related to Lyme disease\(^{210}\)
- Management of neuroborreliosis\(^{211}\)
- Management of Lyme arthritis\(^{212}\)
- Management of Acrodermatitis chronica atrophicans,\(^{213}\) and
- Management of Lyme carditis.\(^{214}\)

\(^{202}\) Lantos et al. (2019)
\(^{203}\) Borchers et al. (2015)
\(^{204}\) Wormser et al. (2006)
\(^{205}\) Lantos et al. (2010)
\(^{206}\) NICE (April 2018a)
\(^{207}\) Lantos et al. (2019)
\(^{208}\) NICE. (April 2018a)
\(^{209}\) NICE (April 2018c)
\(^{210}\) NICE (April 2018d)
\(^{211}\) NICE (April 2018e)
\(^{212}\) NICE (April 2018f)
\(^{213}\) NICE (April 2018g)
\(^{214}\) NICE (April 2018h)
Subsequent to the 2018 NICE guidelines, draft clinical practice guidelines for the prevention, diagnosis and management of Lyme disease were published by IDSA/AAN/ACR, with the recommendations informed by a systematic review and an assessment of the benefits of harms and alternative care options. In contrast to NICE recommendations, IDSA/AAN/ACR recommended for patients with EM, treat with either a 10-day course of doxycycline or a 14-day course of amoxicillin, cefuroxime axetil or phenoxymethylpenicillin rather than longer treatment courses (strong recommendation; moderate quality of evidence). The ISDA/AAN/ACR, citing the systematic review by Lantos et al. (2014), advised there is no clinical evidence to support regimens intended to treat fastidious states of B. burgdorferi infection, such as morphologic variants (aka “cyst” forms, “round” bodies, or “L-forms”), or to treat biofilms.

6.1.2. Relevance of international guidelines to the Australian setting

International treatment guidelines may not be entirely applicable in the Australian health care setting even in patients whom have a travel history overseas to an endemic area. Treatment for Lyme disease in the Australian health care context should only be initiated based on the expert advice of either a consultant physician practising in his or her speciality of infectious disease or a specialist microbiologist. This advice will be based upon results of confirmatory testing conducted in a NATA/RCPA accredited laboratory and/or other clinical findings relevant to informing a treatment decision.

6.1.3. Therapeutic modalities not recommended for treatment of patients with any manifestation of Lyme disease

There is no evidence to support the use of combination antibiotics, immunoglobulin, hyperbaric oxygen, specific nutritional supplements or prolonged courses of antibiotics for the management of Lyme disease. IDSA does not recommend the following therapeutic modalities for treatment of patients with any manifestation of Lyme disease because of a lack of biologic plausibility, lack of efficacy, absence of supporting data, or the potential for harm to the patient:

- first-generation cephalosporins, fluoroquinolones, carbapenems, vancomycin, metronidazole, tinidazole, amantadine, ketolides, isoniazid, trimethoprim-sulfamethoxazole, fluconazole, benzathine penicillin G
- combinations of antimicrobials
- pulsed-dosing (i.e., dosing on some days but not others)
- long-term antibiotic therapy
- empirical antibabesiosis therapy in the absence of documentation of active babesiosis
- anti-Bartonella therapies

---

215 Lantos et al. (2019)
216 Lantos et al. (2014)
217 Lantos et al. (2019)
218 Wormser et al. (2006)
219 Klempner et al (2013)
220 Borchers et al. (2015)
221 Marzec et al. (2017)
222 Lantos et al. (2015b)
223 Wormser et al. (2006)
• hyperbaric oxygen
• fever therapy (with or without malaria induction)
• intravenous immunoglobulin
• ozone
• cholestyramine
• intravenous hydrogen peroxide
• vitamins and nutritional managements, and
• magnesium or bismuth injections.

The strength of recommendation and quality of evidence for this IDSA recommendation for the therapeutic modalities listed above was E-III (Strongly against; Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees).224

More recently a study in 2015 looking to identify websites of clinics that marketed non-antimicrobial therapies for Lyme disease identified more than 30 alternative treatments.225 A review of the medical literature by the authors did not substantiate efficacy or in most cases any rational for the advertised treatments which fell into following several broad categories: oxygen and reactive oxygen therapy; energy and radiation-based therapies; nutritional therapy; chelation and heavy metal therapy; biological and pharmacological therapies ranging from certain medication without recognised therapeutic effects on B. burgdorferi to stem cell transplantation.226

224 Wormser et al. (2006)
225 Lantos et al. (2015b)
226 Ibid.
6.2. **Tick-borne disease known to be acquired in Australia**

Table 3: Initial treatment of Australian tick-borne diseases

**Queensland Tick Typhus**
QTT is readily treated with a short course of doxycycline. Early initiation of doxycycline is critical - a delay in appropriate antimicrobial therapy is associated with increased likelihood of progression to severe disease and complications. 227

Doxycycline should be administered orally in mild-to-moderate infection and intravenously in severe infection. There are no published data on the importance of antibiotics in mild *R. australis* infection although early administration probably prevents hospitalisation and morbidity. 228

Patients usually show marked clinical improvement after 48 hours of antimicrobial therapy. 229, 230

Refer *Therapeutic Guidelines: Antibiotic*. 231

**Q Fever**
The Q fever CDNA National Guidelines for Public Health Units specifies that if Q fever is suspected clinically, empirical treatment should be commenced without waiting for laboratory tests. 232 This recommendation is in the context of a patient with appropriate symptoms AND who are at high risk of contracting the disease.

Refer *Therapeutic Guidelines: Antibiotic*. 233 A two-week course of oral doxycycline is generally used to treat Q fever.

**Flinders Island Spotted Fever and Australian Spotted Fever**
Patients with FISF and ASF are treated with doxycycline. Refer *Therapeutic Guidelines: Antibiotic*. 234

6.3. **Management of patients with persistent symptoms and who remain undiagnosed**

This part of the pathway pertains to management of patients who have debilitating symptoms that cannot be attributed to tick-borne disease or another diagnosable condition.

Where there is no diagnosis and the patient is experiencing symptoms that are medically unexplained, it is especially important to ensure that person-centred care is provided that validates, addresses and manages their symptoms as well as possible.

The Australian Commission on Safety and Quality in Health Care advises that “Person centred-care” involves: 235

- seeking out and understanding what is important to the patient
- fostering trust

227 Stewart et al. (2017)
228 Ibid.
229 Ibid.
230 Graves & Stenos (2017)
231 Therapeutic Guidelines (nd)
232 CDNA (2018)
233 Therapeutic Guidelines (nd)
234 Ibid
235 Australian Commission on Safety and Quality in Health Care (2018)
- establishing mutual respect, and
- working together to share decisions and plan care.

Key dimensions include respect, emotional support, physical comfort, information and communication, continuity and transition, care coordination, access to care, and partnerships with patients, carers and family in the design and delivery of care.\textsuperscript{236}

Patients should be treated symptomatically and are also encouraged to consider the potential for harm with complementary medicines for which there is no evidence in those with comorbidities. All people with MUS, (including those identifying as experiencing the symptoms associated with DSCATT) can be assisted to have an improved quality of life with good care in a partnership between patient and the health care team.

International and Australian guidelines provide evidence-based, practical and consistent recommendations for people that can be applied to patients with the symptom complex described as DSCATT. Good communication and empathy are important. Patients' concerns need to be taken seriously and their symptoms acknowledged and alleviated.

The most common unexplained symptoms reported by patients experiencing DSCATT include fatigue, disordered thinking, sensory disturbance, arthralgia, and headache.\textsuperscript{237} These symptoms can have multiple different causes, depending on the particular symptoms, cluster, and timeframe of symptom(s). For patients with MUS, and equally for patients identifying as experiencing symptoms associated with DSCATT, it is also important to provide support to assist them to manage distressing symptoms and any disability that accompanies them.\textsuperscript{238}

It is important to help patients understand that the mind and body are interconnected in complex ways, and that holistic care is often essential to improve health. It may be useful for the patient to encourage psychological care to address the impact of the illness and underlying issues that may exacerbate symptoms.\textsuperscript{239}

It is important to note that DSCATT is a symptom complex, not a diagnosable disease, and therefore, a patient cannot be given a diagnosis of DSCATT.

For children for whom no diagnosis can be established and who have unresolved symptoms, referral to a paediatrician should be considered.

\textbf{6.3.1. Medically Unexplained Symptoms}

MUS are defined as physical symptoms persisting for more than several weeks and for which adequate medical examination has not revealed a condition that adequately explains the symptoms.\textsuperscript{240} Patients with MUS may be very unwell and require complex care. People experiencing debilitating symptoms attributed to ticks, without any definitive diagnosis could be considered to fall within the definition of MUS. A recent review of MUS guidelines in Europe\textsuperscript{241} estimates that between 3-11 per cent of patients visiting general practice repeatedly consult their GP for MUS. However, this finding might not be entirely applicable to Australia. MUS exist along a

\textsuperscript{236} Australian Commission on Safety and Quality in Health Care (n.d.)
\textsuperscript{237} Brown (2018)
\textsuperscript{238} Stone (2015)
\textsuperscript{239} Ibid.
\textsuperscript{240} Olde Hartman et al. (2017)
\textsuperscript{241} Ibid.
continuum ranging from self-limiting symptoms to recurrent and persistent symptoms through to symptom disorders.

Advice from the RACGP and the review of the international MUS guidelines by Olde Hartman et al summarising guidelines from the Netherlands, Denmark, UK and Germany (two of which provide evidence graded recommendations) is consistent. Patients with MUS often feel stigmatised and not taken seriously. To manage these concerns, all guidelines recommend:

- highlighting the importance of paying attention to the doctor-patient relationship
- providing an individualised approach that recognises the patient’s illness and taking the patient’s symptoms seriously
- demonstrating empathy with consultations aiming to validate the patient’s distress
- highlighting the importance of providing an explanation in the patient’s language about the possible causes of their symptoms (Patients benefit from an explanation that makes sense, removes blame from the patient, generates ideas on how to manage the symptoms. The 2011 UK guidance published by the Royal College of General Practitioners in the UK, advises that GPs should be explicit about their thoughts, uncertainties and expectations of referrals to specialist care), and
- caution that “patients with persistent [medically unexplained symptoms] suffer from their symptoms, are functionally impaired, and are at risk of potentially harmful additional testing and treatment.”

A qualitative study into the experiences of patients identifying with ‘chronic Lyme disease’ reported on the importance of actively engaged and sympathetic clinical encounters. They showed that where patient concerns are fully acknowledged and addressed, they experience greater satisfaction with their healthcare.

Having any chronic medical condition of any cause increases the likelihood of mental health conditions, which in turn can lead to poorer outcomes. An article on managing medically unexplained illness in general practice published by RACGP, notes that acknowledging the difficulty of chronic symptoms and supporting the important mental health strategies is vital to person centred care in chronic disease. Additionally, all patients with MUS need support to manage distressing symptoms and the disability that accompanies them. Helping patients understand that the mind and body are interconnected in complex ways and that holistic care is often essential to improve health is important. Reattribution, the technique of shifting the focus away from only physical symptoms and biomedical diagnoses to a more holistic understanding of illness, was noted as a useful technique in primary care.

6.3.2. Practice Harm Minimisation

International evidence indicates patients with MUS are at risk of potentially harmful additional testing and are often subjected to repeated diagnostic investigations, and unnecessary and excessive testing...

---

242 Stone (2015)
243 Olde Hartman et al. (2017)
244 Chitnis et al. (2011)
245 Olde Hartman et al. (2017)
246 Ali et al. (2014)
247 Stone (2015)
248 Ibid.
249 Ibid.
250 Olde Hartman et al. (2017)
costly referrals and interventions.\textsuperscript{251} An analysis of the Senate submissions noted patients that identified as having DSCATT experience social and financial harms and are at risk of nosocomial harms and may also have sought alternative and potentially non-evidence-based diagnoses and treatments.\textsuperscript{252}

In managing MUS in general practice, balancing the iatrogenic risk of investigation with the therapeutic risk of missing something important, is a challenge for GPs.\textsuperscript{253}

\begin{flushright}
\textsuperscript{251} Royal College of Psychiatrists (RCPSYCH) (2017) \\
\textsuperscript{252} Brown (2018) \\
\textsuperscript{253} Stone (2015)
\end{flushright}
<table>
<thead>
<tr>
<th>Avoid</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Avoid:</strong></td>
<td></td>
</tr>
<tr>
<td>• Repeated diagnostic testing.</td>
<td></td>
</tr>
<tr>
<td>- Harms include worry that there is still something to be found that hasn’t been tested for yet, repeated investigations and treatment, multiple primary care practitioners increased likelihood of false positives, and the finding of minor, non-significant abnormalities in test results that increase anxiety.</td>
<td></td>
</tr>
<tr>
<td>• Use of non-accredited laboratories for diagnostic testing and use of unconventional diagnostic techniques (e.g. kinesiology).</td>
<td></td>
</tr>
<tr>
<td>- Harms include false positives and wrong diagnosis.</td>
<td></td>
</tr>
<tr>
<td>• Unnecessary referrals and interventions.</td>
<td></td>
</tr>
<tr>
<td>- Harms include repeating and extending unnecessary testing and iatrogenic harm as well as financial costs.</td>
<td></td>
</tr>
<tr>
<td>• Treatments with known harm and no benefit (e.g. long-term antibiotics, extreme diets, miracle mineral solution, hyperbaric oxygen treatments).</td>
<td></td>
</tr>
<tr>
<td>- Harms include toxicity, hypersensitivity reactions, predisposition to Clostridium difficile infection, development of antibiotic resistance, line sepsis, severe and persistent vomiting and diarrhoea, and large financial cost without benefit.</td>
<td></td>
</tr>
<tr>
<td><strong>Encourage</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Encourage:</strong></td>
<td></td>
</tr>
<tr>
<td>• Discussion of intended “natural” or alternative therapies for evaluation of individualised harms versus benefits.</td>
<td></td>
</tr>
<tr>
<td>- An awareness of the evidence base and side effects to be aware of can assist patients in choosing alternative therapies wisely and avoiding unnecessary out of pocket costs and unintended harms.</td>
<td></td>
</tr>
<tr>
<td>• Periodic re-evaluation of symptoms and new symptoms to determine an identifiable cause and efficacy of treatment.</td>
<td></td>
</tr>
<tr>
<td>- Small changes over time may not be noticed by patients. Review allows encouragement regarding improvements, detection of deterioration, and evaluation of new symptoms arising.</td>
<td></td>
</tr>
<tr>
<td>• Discussion of possible causes of and treatments for symptoms that have been found on the internet or recommended by friends.</td>
<td></td>
</tr>
<tr>
<td>- Not having a diagnosis is difficult for patients in many ways and leads to a vulnerability to looking for a cause of their symptoms. The internet, social media and social contacts can be spreaders of both good and poor information. Remaining open to a patient discussing what they have found allows for education, exploration of misinformation, identification of reliable sources and identification of potential treatments to trial.</td>
<td></td>
</tr>
<tr>
<td>• Enlistment of other members of a multidisciplinary team.</td>
<td></td>
</tr>
<tr>
<td>• Consideration of mental health strategies.</td>
<td></td>
</tr>
</tbody>
</table>
NPS MedicineWise reports that a poll conducted in 2018 shows almost 7 million Australians take some form of complementary medicine every day.\textsuperscript{254} Without a full understanding of patients’ health practices, including their use of complementary therapies, it is difficult for clinicians to provide safe and patient-centred health care.

In addition to the alternative and complementary therapies reviewed and not recommended for the treatment of Lyme disease (see Section 6.1.3), many of which were reported by patients to the Senate Inquiry\textsuperscript{255} to have been recommended to them, refer to the National Health and Medical Research Council (NHMRC) and Therapeutic Goods Administration (TGA) for information on complementary and alternative medicines in Australia.

A useful resource, \textit{Talking with your patients about Complementary Medicines},\textsuperscript{256} published by the NHMRC has found that many Australians report that they use complementary medicine but do not disclose this information to their clinicians.\textsuperscript{257} One of the most common reasons patients have not discussed their use of complementary medicines is that their clinician has not asked them about it.\textsuperscript{258} The RACGP advises that it is important for GPs to ask patients about their use of complementary therapies and to be aware of the evidence basis, or lack thereof. GPs should also have the knowledge to provide patients with balanced information about potential benefits and risks in order to enable informed decision making.\textsuperscript{259}

The NHMRC resource recommends that:\textsuperscript{260}

- clinicians should be sensitive to the variety of other reasons for patients not disclosing complementary medicines use. These reasons include:
  - a belief that complementary medicines products and therapies are ‘natural’ and ‘safer’ than conventional medicine
  - a feeling of dissatisfaction with conventional medicine
  - a lack of awareness of the risk of unintended drug interactions
  - awareness of the clinician’s attitude to or knowledge of complementary medicines
  - discomfort in raising the topic, and
  - fear of the practitioner’s response
- when clinicians initiate discussions about complementary medicines with their patients, it is important to use an approach that increases collaboration and trust
- clinicians should encourage patients to make treatment decisions based on evidence and can ask their patients if they would like help identifying and interpreting evidence of effectiveness for the complementary therapies they use, and
- clinicians should explain to their patients that all health and treatment decisions involve weighing up potential benefits and potential risks and that this process can help patients to decide whether a treatment is appropriate for them.

Many consumers are not aware of the side effects of some complementary medicine products and their potential interactions with conventional medicines, which may put some users at

\textsuperscript{254} NPS MedicineWise (2019)
\textsuperscript{255} Senate Community Affairs References Committee (2016a)
\textsuperscript{256} National Health and Medical Research Council (NHMRC) (2014)
\textsuperscript{257} Williamson et al. (2008)
\textsuperscript{258} Xue et al. (2007)
\textsuperscript{259} Royal Australian College of General Practitioners (RACGP) (2016)
\textsuperscript{260} NHMRC (2014)
unnecessary risk of harm. Clinicians may need to consider and explain to their patients the risk of adverse reactions (including unintended medicine interactions). Encourage patients to ask questions about the efficacy, risks, contraindications and costs of the complementary therapies and the qualifications of the practitioner.  

If considered clinically necessary, GPs may refer their patient to a pharmacist for a Medicare-supported Home Medicines Review to prevent medication-related problems.

**Further information about Complementary Therapies**

For further information on complementary and alternative medicines in Australia and around the world, refer to:

- NPS MedicineWise

- The Therapeutic Research Center – a US website that has an interaction checker, effectiveness checker and a database of natural therapies
  [https://naturalmedicines.therapeuticresearch.com](https://naturalmedicines.therapeuticresearch.com)

- Memorial Sloan Kettering Cancer Centre has information about herbs, botanicals and a number of complementary therapies

- Cochrane Complementary Medicine
  [https://cam.cochrane.org/cochrane-reviews-related-complementary-medicine](https://cam.cochrane.org/cochrane-reviews-related-complementary-medicine)

- Victoria State Government Better Health Channel

- National Health and Medical Research Council (NHMRC)

- Therapeutic Goods Administration (TGA).

### 6.3.3. The Stepped Care Model

The challenge for the GP involves managing individual symptoms, but also creating a framework for the chronic care of patients with significant ongoing illness.  

The stepped care model of care is internationally recognised and familiar to and widely used by GPs in Australia in all aspects of patient care. The model is recommended for use in patients with medically unexplained symptoms by international and Australian guidelines.

Stepped care is an evidence-based, staged system comprising a hierarchy of interventions, from the least to the most intensive, matched to the individual's needs. Within a stepped care approach an individual will be supported to transition up to higher intensity services or transition down to lower intensity services as their needs change.

As background, international guidelines on MUS recommend a stepped care approach to address three levels of severity of symptoms, which lack clear cut-off points. They also advise that it is

---

261 Cancer Council Australia (2015)
262 Stone (2015)
263 General Practice Mental Health Standards Collaboration (GPMHSC) (2019)
important that one care provider, preferably the GP, keeps control and coordinates the care process.

In addition to being recommended as an approach for managing care for people with MUS, the stepped care service model has been shown in RCTs to be effective for the management of chronic pain, and for the management of depression and anxiety and in the assessment and management of anxiety and depression in adult cancer patients. Stepped care models are widely used in England, Scotland, USA, New Zealand and Australia.

In Australia, the stepped care model of care is familiar to and widely used by GPs in all aspects of patient care. GPs make assessments to determine the best management approach to guide their patients in accessing services appropriate to their level of need, and thus ensure that more intensive and often costly services are directed to patients best able to benefit from them. While referrals are made to other relevant health practitioners as appropriate, it is important that one care provider, preferably the GP, coordinates care.

Stepped care models aim to:

- offer a variety of support options for people with different levels and types of need, from low intensity to high intensity
- provide clear pathways between these care options as individuals’ needs change, and
- improve collaboration and integration between services.

Central to the stepped care approach is the development of an individualised care plan, developed in discussion with the patient.

---

264 US Department of Veterans Affairs (2009)
265 Department of Health (2019)
266 Butow et al. (2015)
266 GPMHSC (2019)
268 Ibid.
Table 5: Overview of Stepped Care approach to managing medically unexplained symptoms

**Step 1: For patients with mild functional limitations and who experience one or several symptoms**

*For patients with mild functional limitations and who experience one or several symptoms:*

- Explore symptoms, conduct physical examination and or additional investigations. List the symptoms.
- Summarise findings discussing clearly what was found and explicitly mentioning what was not found.
- Try to reach a shared definition of the problem. It is important to recognise the symptoms and the fact the patient is troubled by them. Explore and address anxieties and misconceptions. It is very important that the patient’s concerns are treated seriously and in a sensitive manner.
- Provide the patient with targeted and tangible information about ways to manage symptoms and an individualised care plan.

**Step 2: For patients with moderate functional limitations with several symptoms, cluster symptoms or a symptom duration longer than expected**

*For patients with moderate functional limitations with several symptoms, cluster symptoms or a symptom duration longer than expected:*

- Continue GP led care as in Step 1 and if the patient is unable to expand his/her level of activity to an acceptable standard, refer to either primary or secondary care practitioners (e.g. physiotherapy, nurse practitioners, specialist GPs, psychotherapy/CBT).
- Refer to secondary specialist services as required. Telehealth can be used where appropriate.
- Make regular follow-up appointments if functional limitation persists (e.g. every 4-6 weeks).

**Step 3: For patients with severe functional limitations and a large number of symptoms and duration of 3 months or more**

*For patients with severe functional limitations and a large number of symptoms and duration of 3 months or more:*

- Refer to secondary, tertiary care providers and or multi-disciplinary teams or treatment centres.
- Continue to stimulate the expansion of the patient’s functioning and monitor for deterioration in function.
- It is important that one care provider, ideally a GP, coordinates the care provided.
- Limit long term treatments and investigations that are not useful and may even be harmful.
- Make regular follow-up appointments during treatment (e.g. 4-6 weeks).

International guidelines concur that doctor-patient communication is key. They emphasise the importance of exploring patient’s ideas, concerns and expectations, providing acceptable explanations, providing practical and constructive advice that is applicable to their daily lives is important and offering advice on symptom management. Considering the patient’s ethical-cultural background in all steps is also recommended.

---

269 Olde Hartman et al. (2013)
270 Ibid.
7. **ONGOING MANAGEMENT**

7.1. **Lyme disease**

There is a strong body of evidence that does not support ongoing and long-term treatment of Lyme disease with antibiotics.\(^{271, 272, 273, 274, 275, 276, 277, 278, 279}\)

Prolonged intravenous or oral antibiotic therapy for Lyme disease is not recommended in managing patients with Lyme disease in Australia as studies performed in North America and Europe showed these therapies did not significantly improve outcomes and can be associated with significant adverse effects.\(^{280}\)

NICE reviewed the evidence for the management of ongoing symptoms related to Lyme disease and recommended that:\(^{281}\)

- for managing ongoing symptoms of Lyme disease after a course of antibiotics, patients should **not** be routinely offered more than two courses of antibiotics because of a lack of evidence of benefit
- it is important to consider alternative diagnoses to prevent inappropriate antibiotic treatment and misdiagnosis and discussion with a specialist or referral should be considered for some people if a different tick-borne disease is possible, and
- healthcare professionals help people with long term symptoms related to Lyme disease access support if needed.

NICE advised that current treatment of Lyme disease is a single course of antibiotics; however, people who have had treatment for Lyme disease sometimes report ongoing symptoms, the cause of which is often not clear and includes reinfection, or organ damage caused by Lyme disease which may take a long time to heal or may even be permanent.\(^{282}\)

The term ‘ongoing symptoms’ was preferred for the guideline as it does not attribute cause of symptoms; terms such as ‘chronic Lyme disease’ imply possible chronic infection and may be misleading.\(^{283}\)

The CDC in a 2017 Morbidity and Mortality Weekly Report\(^{284}\) advised treatment offered for the diagnosis of ‘chronic Lyme disease’, such as prolonged antibiotic or immunoglobulin therapy, lacks data supporting effectiveness and as such treatment can result in serious complications it is therefore not recommended. Five cases were described to illustrate complications resulting from

---

271 Centers for Disease Control and Prevention (2019)
272 Borchers et al. (2015)
273 Berende et al (2016)
274 Klemmner et al. (2013)
275 Auwaerter et al. (2011)
276 NICE (2018a)
277 NICE (2018i)
278 Lantos et al. (2019)
279 Marzec et al. (2017)
280 Therapeutic Guidelines (2019)
281 NICE (2018a)
282 Ibid.
283 NICE (2018i)
284 Marzec et al. (2017)
unproven treatments, including septic shock, *Clostridium difficile* colitis, osteodiscitis, abscess and death.\footnote{Ibid.}

More recently IDSA/AAN/ACR in their draft Lyme Disease Guidelines recommended against additional antibiotic therapy for patients who have persistent or recurring non-specific symptoms such as fatigue, pain, or cognitive impairment following treatment for appropriately diagnosed Lyme disease, but who lack objective evidence of reinfection or treatment failure (\textbf{Strong recommendation; moderate quality evidence}). IDSA/AAN/ACR noted that evidence of persistent infection or treatment failure would include objective signs of disease activity such as arthritis, meningitis or neuropathy. The recommendation placed high value on avoiding harm due to unnecessary antibiotic exposure or to unnecessary IV access devices. IDSA/AAN/ACR noted the risks of these interventions were not matched by convincing evidence that antibiotics improved patients’ symptom experience or quality of life any better than a placebo.\footnote{Ibid.} To support this recommendation IDSA/AAN/ACR cited several clinical trials\footnote{Lantos et al. (2019)}, \footnote{Klempner et al. (2001)}, \footnote{Kaplan et al. (2003)}, \footnote{Krupp et al. (2003)}, \footnote{Klempner et al. (2013)}, \footnote{Fallon et al. (2008)}, \footnote{Berende et al. (2016)}, \footnote{Stewart et al. (2017)} that had investigated antibiotic treatment of patients with disabling symptoms that had persisted months after standard treatment for documented Lyme disease.

In Australia, an additional course of antibiotics will be determined case by case. Full resolution of symptoms may take some time but does not require further antibiotics.

If symptoms have resolved, the patient exits the Clinical Pathway.

If symptoms persist, consider alternative diagnoses (see \textbf{Section 3.1.1}).

### 7.2. Tick-borne disease known to be acquired in Australia

\textit{QTT}

Delay in correct antimicrobial therapy is associated with increased likelihood of progression to severe disease and complications. However, some individuals, for unknown reasons, progress to severe disease and sepsis despite early doxycycline therapy, with concurrent comorbidities, \textit{Rickettsia} inoculum size and inherent virulence in \textit{Rickettsial} strains being suggested factors.\footnote{Stewart et al. (2017)}

The literature indicates there is little systematic evidence on the outcomes of acute \textit{R. australis} infection, particularly in non-hospitalised patients; however, where severe hospitalised cases with complications have been documented, a full recovery following acute illness is expected. Additionally, there is no evidence of chronic infection. A post infective syndrome of lethargy, malaise and muscle pains persisting for several months or more after acute infection, however, has been described.\footnote{Ibid.}

If symptoms have resolved, the patient exits the Clinical Pathway.

If symptoms persist, consider alternative diagnoses (see \textbf{Section 3.1.1}).
**Q fever**

After treatment of *C. burnetii* primary infection, CDNA guidance includes the following recommendations:

- screening for risk factors of chronic Q fever, including pre-existing valvular heart disease/valvular prosthesis, vascular aneurysms/vascular grafts and immunosuppression
- undertaking a cardiac assessment to assess whether there are underlying abnormalities of the heart valves, and
- monitoring serologically and clinically at 3, 6, 9, 12, 18 and 24 months those who, after acute infection, are at higher risk of chronic Q fever.

Chronic Q fever requires prolonged treatment with antibiotics. Expert advice from a specialist microbiologist or ID physician and other specialist physicians should be sought as appropriate.²⁹⁵ If symptoms have resolved, the patient exits the Clinical Pathway.

If symptoms persist, consider alternative diagnoses (see Section 3.1.1).

### 7.3. Management of patients with persistent symptoms and who remain undiagnosed

The GP will lead the ongoing review of symptoms and management plan, in consultation with the patient, with regular review of progress in achieving their goals. In the event of persistent dysfunction, evaluate the situation regularly and offer any new treatment options. The review and evaluation of new symptoms may require a change of level in stepped care for the patient.

Management of ongoing symptoms should involve a multidisciplinary approach, incorporating the teamwork of all medical specialties relevant to the individual patient’s care. Diagnosis is challenging, and it is important for GPs to seek opinions of experts in vector-borne diseases including specialist microbiologists with diagnostic experience. The management of patients must be a collaborative approach between GPs and specialists. Telehealth can also be used where appropriate.

Consider referring patients who have MUS to appropriate specialists based on best clinical practice and relevant evidence.

If symptoms have resolved the patient exits the Clinical Pathway.
APPENDIX A: CASE STUDIES

Case Study 1 – Rickettsiae infection

Mr A aged 51 years presented with a one-week history of fever, lethargy, anorexia and generalised arthralgia, with a rash and a dry scab, indicative of an insect bite, surrounded by a rash on his back. The patient was afebrile and had no other symptoms.

Further questioning revealed that he had visited the Bunya Mountains National Park, Queensland, for a hiking trip two weeks prior to presentation. He had not travelled overseas. The patient was not aware of being bitten by ticks or other insects. The GP suspected Queensland tick typhus, given this is a common presentation in patients with tick bites who have visited that area and started the patient on doxycycline 100 mg twice daily immediately and referred for tissue biopsy for histopathology and a serological immunofluorescence assay for *Rickettsia australis* at 1:128 titre from an accredited laboratory.

The biopsy confirmed a mononuclear vasculitis consistent with Rickettsial infection but the initial serology was negative. Other blood tests, including liver and renal function tests, were normal.

At review two weeks later, the patient reported that most of his symptoms had resolved and the rash had cleared. Some ongoing minor lethargy persisted. Rickettsial serology was repeated at this time (four weeks after likely bite exposure) and showed an elevated *R. rickettsii* titre. The patient continued to improve and the symptoms fully resolved.

Case Study 2

Mrs Jones, aged 40, lives in Queensland. She’s a farmer/conservation worker/cat breeder. She has not travelled overseas in the last ten years. She thinks she might have been bitten by a tick two years ago. Since around the same time she’s been experiencing muscle pain, including joint pain and swelling. She has no signs of a rash now but when she was bitten she had a rash for a while.

Mrs Jones currently finds physical activity difficult and can no longer walk her dog and maintain a full time job. She’s seen three doctors in the last two years, who have undertaken a range of musculo-skeletal investigations and ruled out arthritis, occupational overuse syndrome, injuries and rheumatoid arthritis (due to her joint pain), but not been able to give her a diagnosis.

She returns to the GP who reviews her clinical history notes. Since Mrs Jones hasn’t been overseas, the GP rules out Lyme disease. The GP notes that Mrs Jones lives in a bushy area with frequent contact with animals, and given her symptoms of lethargy, malaise and muscle pain, suspects tick-borne illness. The GP calls the specialist microbiologist and, following advice, requests relevant diagnostic tests for Australian tick-borne disease. When the tests come back negative, and all other disorders are excluded, the GP develops in coordination with Mrs Jones a comprehensive management plan addressing symptom management and improved overall wellness. This includes referring her to other relevant health practitioners as involved in a multidisciplinary care team as required. Referrals may include, for example, psychologists, physiotherapists, or occupational therapists. The GP continued to see her regularly for medical assessment of progress and medication management of symptoms.

---

Thomas & Wu (2018)
APPENDIX B: BIBLIOGRAPHY


Debilitating Symptom Complexes Attributed to Ticks (DSCATT) Clinical Pathway

clinical trial. *Neurology, 60*(12), 1923–1930. https://doi.org/10.1212/01.WNL.000071227.23769.9E


